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Abstract:  
Purpose: To update the recommendations made by the USPSTF in 2008, on the use of 
sunscreen for primary melanoma prevention.   
Background: Melanoma is a significant and increasing public health problem in the U.S. with 
limited proven, effective preventive interventions.  
Data Sources: MEDLINE, the Cochrane Library, and the U.S. Government Clinical Trials 
Website were searched for relevant articles from 11/01/2008 to 03/08/2012.  Reference lists of 
key articles were hand searched.  
Study Selection: Two reviewers independently screened 264 abstracts and 75 full-text articles 
using predetermined inclusion and exclusion criteria to identify controlled trials, systematic 
reviews, cohort studies, and case-control studies investigating the relationship between 
sunscreen use and melanoma.  Articles were independently appraised, and only good to fair 
quality studies were included in the data synthesis.   
Data Extraction: One reviewer abstracted data from the 4 included articles into a premade data 
extraction table; the information was verified by a second reviewer.   
Data Synthesis and Quality Rating: The results of this review include one good quality 
randomized, controlled trial and one fair quality case-control study.  Both found a decreased risk 
of melanoma associated with regular sunscreen use.  The RCT found a borderline significant 
HR of 0.50 (95% CI: 0.24 -1.02) for all melanoma and a HR of 0.27 (95% CI: 0.08 - 0.97) when 
considering only invasive melanoma.  The case-control study found an adjusted OR for regular 
sunscreen use versus never sunscreen use of 0.44 (95% CI: 0.23 - 0.86).  All other types of 
sunscreen use, including use during outdoor actives, thickness of application, amount of skin 
covered, and reapplication frequency were not associated with melanoma risk.  
Limitations: There were no data on harms associated with sunscreen use.  Included articles 
did not assess the clinically important outcome of melanoma associated morbidity and mortality.   
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Conclusions: There is insufficient evidence to recommend for or against regular sunscreen use 
for melanoma prevention; therefore, we bestowed a grade I recommendation on sunscreen use 
for the prevention of melanoma.   Evidence is also insufficient to recommend for or against other 
types of sunscreen use.  The certainty and magnitude of the evidence is not substantial enough 
to recommend daily sunscreen use for all U.S. Caucasian adults.  Patients at high risk of 
melanoma should be presented with the evidence on sunscreen use and other preventive 
methods and allowed to make a personal decision with their healthcare provider.   
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Introduction:  
Burden of Disease:  
Melanoma will lead to an estimated 76,000 new cases and over 9,000 deaths in the 
United States (U.S.) in 2012.1 The incidence of melanoma is steadily increasing worldwide, 
making melanoma a significant public health problem.2  From 1992 to 2007, the incidence 
increased by 2.2% per year in the U.S.3  Overall melanoma mortality rates have not increased.  
From 2004 to 2008 mortality rates decreased by 2.9% in white women younger than age 50 and 
2.3% in white men younger than age 50;4 conversely, mortality rates in white males over age 50 
increased by 1.0%; rates were stable in white women over age 50.4 
Possible explanations for the increase in incidence include increased exposure to 
ultraviolet (UV) radiation and increased screening by doctors.  An ecological population based 
study found that the increasing incidence rate of melanoma over the past 20 years is correlated 
to an increase in skin biopsy rates over the same time period.5  The melanoma incidence rate 
and skin biopsy rate increased by 2.5 and 2.4 fold, respectively, from 1989 to 2001 in the U.S.5  
This increase in incidence was limited to local disease with no increase in mortality, suggesting 
increased skin biopsy rates are possibly leading to over diagnosis.5  
Males and females have a 10-year survival rate of 71% and 55%, respectively, for all 
tumor sites, types, and levels of invasion.6  Survival rates are not ideal for assessing disease 
morality as they are subject to lead-time bias.  Recurrence rate and mortality are associated 
strongly with primary tumor thickness at diagnosis.7,8  In patients with a primary tumor thickness 
less than 0.5 mm, the 10-year survival rate is 96% versus patients with a primary lesion 4.01 to 
6.0 mm thick, who have a 10-year survival rate of 54%.9  Mitotic index (a ratio of the number of 
mitotic cells over the total number of cells), lymph node invasion, ulceration or bleeding, age, 
location of the tumor, and subtype of melanoma also play a role in mortality.7-9   
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Localized disease is highly curable with wide local excision.10 Currently, we are likely 
over-diagnosing melanoma given the increase in incidence rate without a concurrent increase in 
morality.  Therefore, some melanomas likely never present an overall health risk to the patient 
and do not need to be excised at all. Unfortunately, there are limited effective treatments for 
advanced disease.11  Therefore, prevention and early diagnosis are currently the best methods 
to decrease morbidity and mortality from melanoma.   
Risk Factors:  
Family history is considered an important risk factor for melanoma.  A meta-analysis of 
11 case-control studies with non-significant inter-study heterogeneity found a relative risk of 
1.74 (95% CI: 1.41 - 2.14) for a history of one of more first degree family members with 
melanoma.12  Even so, only a small number (less than 7%) of melanoma cases are attributed to 
family history.13 There are also familial genetic syndromes where multiple family members in 
several generations develop melanoma; the most common gene implicated in multiple familial 
melanoma is CDKN2A.14  
A personal history of melanoma is a risk factor for a second primary melanoma.15  A 
population based study found a 5% risk for a second primary melanoma over twenty years for 
patients with cutaneous melanoma.15  A history of squamous cell carcinoma or basal cell 
carcinoma is also associated with an increased risk of melanoma, likely due to the influence of 
sun exposure in both types of cancer.16 
Several case-control studies found that multiple normal and atypical nevi are associated 
with an increased risk of melanoma.17-19  Atypical or dysplastic nevi are likely associated with a 
higher risk of melanoma than normal nevi.19  The immune system also likely plays a role in the 
development of melanoma; transplant patients and other immunosuppressed individuals are at 
an increased risk of developing melanoma.20 
People with a phenotype more sensitive to UV radiation, including fair skin, blond or red 
hair, and light eye color, are at an increased risk for developing melanoma.12  The Fitzpatrick 
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skin type classification system is often used to standardize characterization of skin type in 
studies.21 The system uses skin color and propensity to burn or tan to classify individuals into 
six categories (see Appendix C).   People with Fitzpatrick skin type I and II are at an increased 
risk for melanoma.12  A meta-analysis of 23 case-control studies found a relative risk of 2.09 
(95% CI: 1.67 - 2.58) for skin type I compared to people who never burn and tan easily 
(heterogeneity Chi-square p-value < 0.001).12  A high density of freckling versus no or minimal 
freckling was found to have a relative risk of 2.10 (95% CI: 1.80 - 2.45) for development of 
melanoma in the same meta-analyses using 32 case-control studies.12  There is some 
uncertainty about this estimate, because the pooled studies often characterized freckling 
differently.   
UV radiation is the only known modifiable risk factor for the development of melanoma.22  
The link between UV exposure and melanoma is less clear than for other types of skin cancer.  
The evidence is based on observational studies with limited external validity and consistency.23   
Observational studies have found an increased risk of melanoma with intermittent 
severe sun exposure, especially during childhood, more so than chronic sun exposure.12,24  
Three meta-analyses found an odds ratio (OR) of 1.6 - 1.7 (95% CI: 1.3 - 1.9) for intermittent 
sun exposure versus an OR of 0.7 - 0.9 (95% CI: 0.6 - 1.0) for chronic sun exposure.12,25,26  A 
history of sunburn, especially during childhood, is consistently associated with a risk of 
melanoma.  A meta-analysis found a relative risk of 2.2 (95% CI: 1.6 - 3.1) for sunburn and the 
development of melanoma.23  It also appears that the latitude at which people live plays a role in 
the risk for melanoma.  Latitude affected the relative risk estimates for the effect of sunburn and 
freckling on melanoma risk and could be confounding these relationships.12,23   
Melanoma also develops on areas of the body not exposed to the sun, suggesting 
heterogeneity in the pathogenesis of the disease, especially in certain familial syndromes.27  
There are four main histological subtypes of melanoma: superficial spreading, lentigo maligna, 
acral lentiginous, and nodular; each type has its own associated risk factors.  Currently all 
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identified risk factors for melanoma have limited predictive value given ORs and RRs in the 
range 1-2.  More research is needed to understand this heterogeneous disease and its complex 
interaction with UV radiation.   
Screening:  
 Currently, the most common screening method for melanoma is whole body visual 
inspection of the skin by a physician or self-examination. The United States Preventive Services 
Task Force (USPSTF) does not recommend screening for melanoma.  The American Cancer 
Society, Skin Cancer Foundation, and the American Academy of Dermatology do recommend 
monthly self-skin exams and regular physician skin checks for people over age 50.28  The 
evidence to support the use of visual skin inspection to reduce melanoma mortality is limited.  A 
systematic review performed by the USPSTF in 2005 found insufficient evidence to assess the 
accuracy of screening or its effect on morbidity and mortality.29  There are no randomized, 
controlled trials of screening; the USPSFT statement is based on poor to fair quality 
observational studies with limited ability to prove causation. Harms associated with screening, 
including over-diagnosis, over-treatment, and psychological harm, have not been well studied.   
 Dermatoscopy and digital dermatoscopy are new diagnostic tools used to assist in 
melanoma diagnosis.  One meta-analysis of nine studies found dermatoscopy, compared to 
examination with the naked eye, can improve the sensitivity of melanoma diagnosis with an OR 
of 9.0 (95% CI: 1.5 - 54).30  There is also evidence from an observational study of 1865 excised 
lesions that digital dermatoscopy can decrease the number of excised pigmented lesions.31  
Both of these tools have the potential to improve screening accuracy and decrease over-
treatment, but they have not been evaluated in screening populations.  More research is needed 
to fully characterize their ability to improve screening and diagnosis.    
Diagnosis:  
 Melanoma is diagnosed by microscopic examination of a skin biopsy by a pathologist or 
dermatopathologist.  The thickness of the primary tumor, the presence of ulceration, and the 
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mitotic rate (the number of cells undergoing mitosis) are evaluated.  A research study evaluating 
the accuracy of melanoma diagnosis using visual microscopic evaluation found that among 8 
expert pathologists, there was disagreement about the diagnosis in 38% of the 37 specimens.32  
This suggests we need a stricter definition and diagnostic criteria for melanoma.   
Current Prevention Practice:  
Logically, the use of preventive methods that decrease exposure to UV radiation should 
protect against the development of melanoma, given that UV radiation is an identified risk factor.   
Controversy remains in the literature over which preventive methods, if any, are effective, 
including protective gear, sunscreen, and reducing tanning bed use.24  
Protective Clothing: The effect of protective clothing on melanoma prevention is not 
well researched.  Observational studies have shown that children who wear a shirt all the time 
when outside or wear more clothing on vacations develop less nevi.33,34  The direct effect of 
protective clothing on melanoma is unknown.   
Tanning Bed Use: A systematic review of 1 fair quality cohort study and 10 fair quality 
case-control studies found that regular tanning bed use many increase the risk of melanoma 
(OR ranging from 1.55 to 2.3).24  The certainty of the evidence is limited by observational study 
designs with un-validated and varying measures for tanning bed use.   
Sunscreen:  Daily sunscreen use for 4.5 years was found to protect against the 
development of squamous cell carcinoma in a randomized, controlled trial of 1383 participants 
conducted in Queensland, Australia.35  This trial was not placebo controlled (controls were 
allowed discretionary sunscreen use) and a significant number of patients did not participate in 
active follow-up. Other studies have evaluated the effect of sunscreen on actinic keratosis, but 
only about 60% of squamous cell cancers arise from actinic keratosis, making this a poor 
intermediate outcome.36  The effect of sunscreen on basal cell carcinoma is even more poorly 
defined; most studies have found no effect.24 
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Sunscreen’s effect on melanoma is unknown and controversial.  This effect is difficult to 
study because the main determinates of sunscreen use, such as fair skin, a tendency to burn, 
sun exposure, and a family history of melanoma, are also risk factors for melanoma.  Therefore, 
it is very important, and difficult, to control for these confounders.   
The issue is further complicated because UV radiation is comprised of both UV A (UVA) 
radiation and UV B (UVB) radiation.  UVA radiation (about 95% of the total incident UV light) is 
the main type of UV radiation implicated in the development of melanoma.24,37  Conversely, UVB 
radiation (about 5% of the total incident UV light) confers a possibly protective effect.2437  Until 
1989, most sunscreens only protected against UVB radiation, with limited ability to absorb 
UVA.24  Also, while sunscreens have been formulated to be sweat or water-proof, the 
effectiveness of these new formulations is unknown.  Studying the effect of sunscreen on 
melanoma is further complicated by varying Sun Protection Factors (see Appendix D), and 
incorrect application methods.  Often times, sunscreen is not applied to the correct thickness 
and users do not reapply after water exposure, sweating, or prolonged sun exposure.38  These 
details make the timing of studies, the type of sunscreen used, and the application process a 
critical factor to study.   
Several observational studies and randomized, controlled trials have evaluated the effect 
of sunscreen use on the development of nevi in children, with mixed results.39-42,43  A 
randomized, controlled trial conducted in British Columbia found children in the sunscreen group 
developed a median of 24 nevi, versus 28 nevi (p = 0.048) in the control group, over 3 years.43  
The development of nevi is an intermediate outcome and its effect on the future development of 
melanoma is unknown.  
 Past systematic reviews and studies evaluating the direct effect of sunscreen on 
melanoma incidence have conflicting results, with most studies finding no effect or an increased 
risk of melanoma with sunscreen use.24  The current evidence is based on poor to fair quality 
observational studies with inadequate measures of sunscreen use and sun exposure.  Given 
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the current controversy over the effect of sunscreen on melanoma, we will evaluate the 
literature for new, high quality studies, in the hope of further clarifying the issue.   
Previous USPSTF Recommendations:  
The USPSTF conducted an updated systematic review in 2008 and concluded that the 
evidence was insufficient to recommend for or against the use of sunscreen to prevent 
cutaneous melanoma.24  The review evaluated one fair quality cohort study and four fair quality 
case-control studies. Case-control studies are not ideal for determining causation and often 
over-estimate the effect of an intervention.  Two studies found no effect of sunscreen use on 
melanoma risk; one study found a protective effect for women using daily screen versus 
occasional or never use; and two studies found harmful effects, with an increased risk of 
melanoma for people who reported always or almost always using sunscreen.24  All of these 
studies had significant limitations from unadjusted confounders and fair external validity from 
homogenous populations.24 
Purpose:  
 The purpose of this review is to update the recommendations made by the USPSTF on 
the use of sunscreen for melanoma prevention.  Significant studies have been published since 
the last update conducted by the USPSTF in 2008. There has also been a change in the 
formulation of sunscreens over the last 30 years, which makes a comparison of old and new 
studies invalid.  In this review, we will consider the newest evidence in order to make a 
recommendation on the effectiveness of sunscreen for melanoma prevention.  
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Methods:  
 
Table 1: Key Question 
Key Question  Does sunscreen use compared to no 
sunscreen use decrease the incidence of 
primary cutaneous melanoma in 
Caucasians? 
 
Inclusion and Exclusion Criteria:   
 As this is an update to the USPTF review, the inclusion and exclusion criteria used for 
this study were the same as previously described (see Table 2).  We included any population of 
patients or location, as long as a detailed description of environmental risk factors and 
demographic information was included in the study.  We excluded studies where the population 
and location were not described.  This requirement was due to the fact that information about 
latitude, sun exposure, skin type, and family history are very important factors in our review to 
help understand the role of potential confounding.  We considered trials of younger patients, 
age 12 - 50, separately from trials of older patients (50 and older), because the disease is likely 
different in these two age groups.6  We also excluded studies on patients with known genetic 
conditions, such as Xeroderma Pigmentosum, because the biological effect of sunscreen on the 
development of melanoma may be different in these patients compared to the general 
population.  Our intervention is the use of any sunscreen as long as a description of the use is 
included: duration, Sun Protection Factor (SPF), location, and amount.  We considered limiting 
our inclusion criteria to studies with an SPF of 15 or higher, because there is evidence that 
sunscreen below SPF 15 is less effective.(cite)  We decided against this limitation because the 
USPSTF did not limit studies based on SPF; we will consider the SPF of sunscreen used in the 
studies when evaluating their results.  We also considered the type of UV protection in the 
sunscreen used; we evaluated studies with UVA-only protection separately from studies with 
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UVA and UVB protection.  We excluded studies that evaluated sun-tanning lotion, as these 
products offer very limited sun protection factor, if any.   
 Our comparison group was no, discretionary, or less sunscreen use.  We did not limit 
our comparison to no sunscreen use because randomized, controlled trials cannot ethically use 
a placebo.  Our outcome of interest was the incidence of melanoma.  We also included studies 
evaluating morbidity and mortality due to melanoma.  Ideally, we would have only included 
studies evaluating mortality, given this is the most clinically important outcome.  However, given 
the natural history of melanoma, exposure often occurs years before onset of disease.  We do 
not expect to find many studies that are long enough to evaluate mortality as an outcome.  We 
will included the four major subtypes of cutaneous melanoma, because other types of 
melanoma may have different pathogeneses and risk factors.   No secondary outcomes were 
included, such as sunburn or nevi, as they are not clinically relevant and would require a 
different search strategy.   
We chose a minimum of 10 years of follow-up for RCT and cohort studies.  Ideally, the 
length of follow-up would have been longer, given the length of time from exposure to outcome 
in melanoma, but the current literature is not robust enough to support this limit.  We did not set 
a limit of the duration of sunscreen use, but considered this factor when evaluating the studies.   
We limited our review to randomized, controlled trials, cohort studies, and nested or 
population case-control studies.  We considered excluding case-control studies, as they often 
over-estimate the effect of an intervention.  However, we decided to include case-control 
studies, because they were included in the USPSTF review and there are limited randomized, 
controlled trials and cohort studies published on this topic.  We took into account the limitations 
of case-control studies when rating the overall quality of evidence.  We excluded ecologic 
analyses, hospital-based case-control studies, cross-sectional studies, case-series, and case 
reports, as all of these study designs are poor at establishing a causal relationship.   
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Table 2: PICOTTSS Inclusion and Exclusion Criteria 
Population: 
Inclusion: 
 
 
 
Exclusion:  
Any population, as long as description of 
population and environmental risk factors is 
provided.  Any location. 
Studies where population characteristics (skin 
pigmentation) and environmental risk factors 
(latitude, sun exposure) are not described.   
People with melanoma due to known genetic 
syndromes like Xeroderma Pigmentosum. 
Intervention:  
Inclusion: 
 
 
Exclusion: 
Sunscreen use, with description of use 
included (SPF, duration, location).  Trials with 
UVB vs. UVA/UVB will be considered 
separately. 
Sun tanning lotion.   
Comparator:  No, discretionary, or less sunscreen use  
Outcomes:  
Inclusion: 
 
 
 
 
Exclusion: 
Incidence of cutaneous melanoma, including 
the four major subtypes: superficial spreading, 
nodular, lentigo maligna, and acral lentiginous.  
Subungual melanoma, mucosal melanoma, 
ocular melanoma, and pre-pubertal melanoma 
Time allowed for outcomes to appear: 10 years of follow-up for controlled trials and 
cohort studies. No limit on duration of 
intervention.   
Time over which literature was searched: November 2008 to March 2012 
Study Design: 
Inclusion: 
 
 
 
 
Exclusion: 
Systematic reviews, randomized and non-
randomized clinical trials and cohort studies, 
nested case-control studies and population-
based case-control studies 
 
Ecologic analyses, hospital-based case-
control studies, cross-sectional studies,  
case-series, case reports 
Setting:  Any  
 
Literature Search:   
We searched for articles published from November, 2008 to March, 2012 in MEDLINE 
and the Cochrane Library.  We chose a start date of November, 2008, as this is an update to 
the USPSTF systematic review ending in November, 2008.   The U.S. government clinical trials 
website was searched to look for on-going and unpublished studies.  The search terms included 
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“melanoma”, “skin cancer,” and “sunscreen agents.”  All of the search terms used are Medical 
Subject Headings (MeSH) terms.  A full explanation of the search strategy can be found in 
Appendix E; these are the same search terms and databases as the 2008 USPSTF review.   
Articles were also obtained from the reference lists of key studies identified in the search.  We 
consulted with a health science librarian about our search strategy and utilized her 
recommendations.  We did not limit the search to humans or articles published in English to 
capture articles recently added to MEDLINE that were not yet indexed.  The last search was run 
on May 20, 2012 to look for articles published since the start of the review.   
Article Review and Data Abstraction:  
Two reviewers independently reviewed the title and abstracts identified in the search 
using the predetermined inclusion and exclusion criteria.  The first author reviewed all of the 
articles; the second author reviewed only articles excluded by the first reviewer.  All articles 
included by either reviewer were included in the full text review.  Articles without an abstract 
were automatically included in the full text review.   
One reviewer obtained copies of all included full text articles.  Both reviewers 
independently reviewed all of the articles included in the full text review using the predetermined 
inclusion and exclusion criteria.  Reasons for exclusion were recorded and reported in Figure 1 
and Appendix F.  Disagreements between the reviewers during full text review were resolved by 
discussion and consensus; if a consensus could not be met, it was planned for a third reviewer 
to resolve the disagreement.  One reviewer abstracted data into evidence tables for all studies 
included after full text review; a second reviewer verified the results for accuracy.  A data 
extraction table was developed based on the Cochrane Consumers and Communication Review 
Group’s data extraction template and tables used in the 2008 USPSTF review (see Appendix G 
for a sample data extraction table).  Information was extracted from each study for 
characteristics of study participants (demographic information, sun exposure history, and sun 
protection use history), type of intervention (type, dose, duration, location, and frequency of 
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sunscreen use), type of outcome measure (incidence of melanoma, morbidity and mortality, 
harms, and other outcomes measured).    
Quality Assessment and Risk of Bias:    
We rated the internal validity of all of the articles included in the study using the same 
process as the USPSTF systematic review: the USPSTF’s study-design specific quality criteria 
supplemented by the Newcastle-Ottawa Scale for assessing cohort and case-control studies 
and the National Institute for Health and Clinical Excellence (NICE) Methodology Checklists 
(see Table 3).24  The USPSTF study design-specific criteria were used as a guideline to rate the 
internal validity of 5 different study types: systematic reviews, case-control studies, randomized, 
controlled trials, cohort studies, and diagnostic accuracy studies.44  The overall internal validity 
of the study was then given a grade of good, fair, or poor (see Table 4).  The USPSTF also 
gave the study a rating based on the study design (see Table 5).44 
The Newcastle-Ottawa Scale was developed to assess the internal validity of non-
randomized studies in meta-analyses.  The scale evaluates case-control studies on three main 
areas: selection of cases and controls, comparability of cases and controls, and the 
ascertainment of exposure.45  Each study is then given a star rating for each of the three 
categories.  The content validity and inter-rater reliability of the scale was evaluated and 
approved by experts in the field.  The criterion validity and construct validity are still being 
assessed.45   
The NICE Methodology Checklists are used to evaluate the internal validity of studies in 
the development of NICE clinical guidelines.46 The checklists are study type-specific; 
randomized, controlled trials are evaluated for selection bias, performance bias, attrition bias, 
and detection bias; systematic reviews are evaluated for a focused key question, methodology 
description, literature search, quality rating of individual studies, and relevance to your key 
question; case-control studies are evaluated for a focused key question, the selection of 
participants, measurement bias, confounding factors, and the statistical analysis.      
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For this study, an overall internal validity rating was given to each individual study by 
combining the ratings from the three internal validity rating criteria.  Studies were given an 
internal validity, external validity, and overall quality rating of good, fair, or poor based on the 
qualitative assessment (see Table 4).44  A good quality study was given a positive answer to all 
of the quality criteria.  A fair study had one or more negative quality criteria, and a poor study 
had significant limitations that nullify the results.  Poorly rated studies were not included in the 
overall strength of the evidence rating.   
Table 3: Quality Rating Criteria 24 
Design     
 
USPSTF Quality 
Rating Criteria44 
 
NICE Methodology 
Checklists46 
Newcastle-Ottawa 
Quality  
Assessment 
Scales45 
Systematic reviews 
and Meta-analyses  
 
• Comprehensiveness of 
sources considered/search 
strategy used  
• Standard appraisal of 
included studies  
• Validity of conclusions  
• Recency and relevance are 
especially important for 
systematic reviews  
 
• Study addresses an 
appropriate and clearly 
focused question  
• Description of the 
methodology used is included  
• Literature search is 
sufficiently rigorous to identify 
all relevant studies  
• Study quality is assessed 
and taken into account  
• There are enough similarities 
between the studies selected 
to make combining them 
reasonable  
N/A 
Case-control studies 
 
• Accurate ascertainment of 
cases  
• Nonbiased selection of 
cases/controls with exclusion 
criteria applied equally to both  
• Response rate is reported  
• Diagnostic testing 
procedures applied equally to 
each group  
• Measurement of exposure 
accurate and applied equally 
to each group  
• Appropriate attention to 
potential confounding 
variables  
 
• Study addresses an 
appropriate and clearly 
focused question  
• Cases and controls are 
taken from comparable 
populations  
• Same exclusion criteria are 
used for both cases and 
controls  
• Percentage of each group 
(cases and controls) that 
participated in the study is 
reported  
• Comparison is made 
between participants and non-
participants to establish 
similarities or differences  
• Cases are clearly defined 
and differentiated from 
controls  
• It is clearly established that 
controls are non-cases  
• Measures have been taken 
to prevent knowledge of 
primary exposure influencing 
case ascertainment  
• Exposure status is measured 
in a standard, valid, and 
• Case definition is adequate  
• Cases are representative  
• Controls are from the same 
population as cases  
• If cases are first occurrence 
of outcome, then controls 
have no history of this 
outcome  
• Cases and controls are 
matched, and/or confounders 
are adjusted for in the analysis  
• Same method of exposure 
ascertainment for cases and 
controls  
• Acceptable ascertainment of 
exposure  
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reliable way  
• Main potential confounders 
are identified and taken into 
account in the design and 
analysis  
• Confidence intervals are 
provided  
 
Randomized, 
controlled trials 
 
• Initial assembly of 
comparable groups employs 
adequate randomization, 
including first concealment 
and whether potential 
confounders were distributed 
equally among groups  
• Maintenance of comparable 
groups (includes attrition, 
crossovers, adherence, 
contamination)  
• Important differential loss to 
follow-up or overall high loss 
to follow-up  
• Measurements are equal, 
reliable, and valid (includes 
masking of outcome 
assessment)  
• Clear definition of the 
interventions  
• All important outcomes 
considered  
 
• Study addresses an 
appropriate and clearly 
focused question  
• Assignment of subjects to 
treatment groups is 
randomized  
• An adequate concealment 
method is used  
• Subjects and investigators 
are kept blind about treatment 
allocation  
• Treatment and control 
groups are similar at start of 
trial  
• Only difference between 
groups is the treatment under 
investigation  
• All relevant outcomes are 
measured in a standard, valid, 
and reliable way  
• Percentage of individuals or 
clusters recruited into each 
treatment arm that dropped 
out before study completion is 
reported  
• All subjects are analyzed in 
the groups to which they were 
randomly allocated (often 
referred to as intention-to-treat 
analysis)  
• When the study is carried out 
at more than one site, results 
are comparable for all sites  
N/A 
 
Table 4: Definition of Quality Ratings44 
Quality Rating:  Definition: 
Good Meets all applicable criteria.  Low risk of 
bias. Results are considered valid.   
Fair Fails to meet one or two applicable criteria.  
Some risk of bias.   
Poor The study has a significant risk of bias that 
invalidates the results. 
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Table 5: USPSTF Hierarchy of Research Design44 
Rating Study Design  
I Evidence obtained from at least one 
properly randomized, controlled trail 
II-1 Evidence obtained from well-designed 
controlled trials without randomization 
II-2 Evidence obtained from well-designed 
cohort or case-control analytic studies; 
preference from more than one center or 
research group.   
II-3 Evidence obtained from multiple time 
series with or without the intervention. 
Dramatic results in uncontrolled 
experiments could also be regarded as this 
type of evidence.   
III Opinions of respected authorities, based 
on clinical experience, descriptive studies 
and case reports, or reports of expert 
committees.  
 
Data Synthesis: 
When possible, we pooled data from randomized, controlled trials or cohort studies.  We 
believed the ability to do a quantitative analysis was unlikely.  We expected to find studies with 
varied study designs and populations. Meta-analyses performed in the past on this topic have 
had limited validity; they pooled data from several heterogeneous poor to fair quality case-
control studies.47,48  When the original studies have intrinsic flaws pooling the results does not 
improve the quality of the evidence.  Therefore, we only planned to perform a quantitative 
analysis if we determined there were several good quality studies of the same design, 
population, and sunscreen formulation.   
Strength of Evidence:  
We rated the overall strength of the evidence using the methods of the USPSTF.44,49  
The use of sunscreen to prevent melanoma was given a letter grade based on the certainty and 
magnitude of the evidence for a net benefit (see Table 6).  First we judged the certainty of the 
evidence for an overall net benefit as high, moderate, or low based on six key questions (see 
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Table 7 and Table 8).  The magnitude of net benefit in the general population was estimated as 
substantial, moderate, small, or zero/negative (no benefit or harm).  An outcomes table of 
potential benefits and harms of sunscreen use was used to help estimate the magnitude of net 
benefit.  The ratings for certainty and magnitude of net benefit were combined to give an overall 
letter grade for the use of sunscreen to prevent melanoma (see Table 6).   
Table 6: USPSTF Recommendation Grid49  
Certainty of Net Benefit Magnitude of Net Benefit 
 Substantial Moderate Small Zero/Negative 
High  A B C D 
Moderate B B C D 
Low  Insufficient 
 
Table 7: Questions Considered by the USPSTF for Evaluating the Overall Certainty of the 
Evidence of Net Benefit for the Preventive Service49  
1. Do the studies have the appropriate research design to answer the key 
question(s)? 
2. To what extent are the existing studies of high quality? (i.e., what is the 
internal validity?) 
3. To what extent are the results of the studies generalizable to the general 
U.S. primary care population and situation? (i.e., what is the external 
validity?) 
4. How many studies have been conducted that address the key question(s)? 
How large are the studies? (i.e., what is the precision of the evidence?) 
5. How consistent are the results of the studies? 
6. Are there additional factors that assist us in drawing conclusions (e.g., 
presence or absence of dose–response effects, fit within a biologic 
model, etc?)? 
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Table 8: USPSTF Levels of Certainty Regarding Net Benefit49 
Level of Certainty Description 
High The available evidence usually includes 
consistent results from well-designed, well-
conducted studies in representative primary 
care populations. These studies assess the 
effects of the preventive service on health 
outcomes. This conclusion is, therefore, 
unlikely to be strongly affected by the results 
of future studies. 
Moderate The available evidence is sufficient to 
determine the effects of the preventive service 
on health outcomes, but confidence in the 
estimate is constrained by such factors as: the 
number, size, or quality of individual studies, 
inconsistency of findings across individual 
studies, limited generalizability of findings to 
routine primary care practice, or lack of 
coherence in the chain of evidence.  As more 
information becomes available, the magnitude 
or direction of the observed effect could 
change, and this change may be large enough 
to alter the conclusion. 
Low The available evidence is insufficient to assess 
effects on health outcomes. Evidence is 
insufficient because of: the limited number or 
size of studies, important flaws in study design 
or methods, inconsistency of findings across 
individual studies, gaps in the chain of 
evidence, findings that are not generalizable to 
routine primary care practice, or a lack of 
information on important health outcomes.  
More information may allow an estimation of 
effects on health outcomes. 
 
 Results:  
Study Selection:  
A flow diagram of our search results is shown in Figure 1.  Our initial search identified 
259 articles for abstract and title review.  We also identified 5 articles by hand searching the 
reference lists of 15 key studies.  After abstract review, 75 articles remained for full text review.  
A reference list and reason for exclusion of articles excluded during full text review can be found 
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in Appendix E.  There were 3 disagreements between the reviewers during full text review that 
were decided by consensus; one of the articles was included.  The other two articles were 
excluded; one evaluated sunscreen use in patients with a previous diagnosis of cutaneous 
melanoma and the other had an outcome of sunburn, not melanoma.  A large majority of the 
articles (42 out of 71) were excluded due to the wrong study design or publication type.  These 
included mostly news articles, opinion pieces, and non-systematic reviews.  Of the other 71 
excluded articles, 2 reported data in another article, 7 were not in English, 4 did not evaluate the 
intervention of sunscreen use, 11 had not evaluated melanoma as an outcome, and 4 evaluated 
the wrong population.  The 2008 systematic review conducted by the USPSTF was excluded, 
because it is the study we are updating.  Its findings are summarized in the Introduction.24  We 
were left with 4 studies for quantitative review: 1 randomized control trial, 1 systematic review, 
and 2 case-control studies.  One of the case-control studies and the systematic review were 
judged as poor quality during the review and excluded. 
Summary of Studies Excluded Due to Poor Quality Rating: 
Both of the studies excluded during the quality review had significant limitations that 
invalidated their results.  The systematic review by Birgitta Kutting and Hans Drexler was 
conducted in Germany to give an overview of occupational exposure to UV radiation and to 
provide an evidence-based recommendation on effective UV radiation exposure prevention in 
the workplace.50 The review gave limited information about their methods: there was no 
inclusion or exclusion criteria, flow diagram, or a description of their returned search results.  
They did provide a list of search terms, but there is not enough information to determine how 
they selected their final 12 articles.  There is no mention of quality rating of the included studies.  
Only 2 of the 12 studies included in the review looked at melanoma, but neither specifically 
addressed the relationship between sunscreen and melanoma.  Their recommendation on the 
use of sunscreen to prevent UV radiation exposure and melanoma in the work place is based 
on articles not included in the review.  This article is more similar to a critical review than a 
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systematic review.  Our quality rating details for the study using the USPSTF quality rating 
criteria and Nice Methodology Checklist can be found in Tables 9 and 12, respectively.   
The case-control study was conducted in Prague, Czech Republic by J Varnova, M. 
Arenbergerova, P Arenberger, et al. The aim of the study was to determine risk factors 
associated with cutaneous melanoma and determine if behaviors associated with melanoma 
risk increased in young people versus older people, which could account for the increasing 
incidence of melanoma.51  The study used a one-time self-administered survey to collect sun 
exposure and sun protection information on cases, old controls, and young controls.    
There were significant differences between the ages of each group, with cases 
averaging 53.6 years, old controls averaging 51.1 years, and young controls averaging 19.9 
years. The goal of this study was to compare melanoma risk factors in different age groups, but 
age is a known risk factor for melanoma; therefore, it is an uncontrolled confounder in the 
relationship between sunscreen use and melanoma.  They did not report information about 
those eligible to participate versus those that did participate in the survey.  The two control 
groups were selected from different populations and the older control group was self-selected 
by they responding to a posted flyer.  Additionally, the measure of exposure (sunscreen use) 
was obtained from an unvalidated self-survey.  Participants were asked about sunscreen use at 
only two time points: childhood and adulthood. They were placed into 3 poorly defined groups: 
“never users, “occasional users,” and “regular users” (more than 5 times per sun tanning).  They 
were not asked about SPF used, location applied, reapplication, or type of UV protection.  The 
study did not take into account when the melanoma was diagnosed in the cases, which is 
another source of potential confounding because previous melanoma diagnosis may affect 
sunscreen use habits.  The quality rating results for the Varnova article using the USPSTF 
quality rating criteria, NICE Methodology Checklist, and Newcastle-Ottawa Quality Assessment 
Scales can be found in Tables 10, 11, and 12, respectively. 
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Study Characteristics of Studies Included in the Final Review: 
The two studies included in the final review and evidence synthesis were a RCT and a 
case-control study published in English.  The randomized, controlled trial by Adele Green, Gail 
M. Williams, Valerie Logan, and Geoffrey M. Strutton was conducted in Queensland, Australia; 
the trial lasted 4 years, with 11 years of follow-up.52  The case-control study by DeAnn Lazovich, 
Rachel Isaksson Vogel, Marianne Berwick, et al. was a one-time telephone survey conducted in 
Minnesota that evaluated sun exposure and sunscreen use over each decade of life.53   
The studies evaluated a total of 3889 participants: 1621 in the RCT and 2268 in the 
case-control study.  The Green RCT participants were randomly selected 25 to 75 year olds, 
with no other specified inclusion or exclusion criteria.  Participants with previous melanoma 
were not excluded from the study.  The Lazovich participants were age 25 to 59, living in 
Minnesota, with no prior diagnosis of melanoma and no language barrier.   
The intervention in the Green trial was daily use of SPF 16 sunscreen applied to the 
hands, neck, and arms every morning, with reapplication after sweating, water exposure, or long 
sun exposure for 4 years.  Participants were given a free, unlimited supply of sunscreen. 
Compliance was measured with sunscreen bottle weights and questionnaires asking about 
average frequency of use in a normal week.  Controls were allowed discretionary sunscreen 
use, as the use of a placebo was deemed unethical.  In the Lazovich study cases and controls 
were asked about sunscreen use of SPF 15 or greater in each decade of life during different 
outdoor actives and when not specifically doing an outdoor activity.  Participants were asked 
about frequency, thickness, location, and reapplication after more than 2 hours of sun exposure. 
Lifetime sunscreen use was obtained by averaging a participant’s use within each decade and 
across all decade years.  Users were also classified as “non-,” “inconsistent,” and “optimal 
users” based on the last two decades.   
Neither study evaluated our ideal outcome of melanoma related morbidity and morality.  
In the Green RCT, melanoma incidence, evaluated with a hazard ratio, was a secondary 
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outcome.  The study did report overall mortality or melanoma thickness.  The Lazovich case-
control study reported an odds ratio (OR) for different types of sunscreen use and melanoma 
risk.  Due to inherent limits of the design, a case-control study cannot evaluate incidence.  
Neither study addressed harms or quality of life associated with sunscreen use.  See Table 14 
for study characteristics for the Green RCT and Table 13 for characteristics of the Lazovich 
case-control study.  
Risk of Bias within Studies: 
The potential for selection bias, measurement bias, confounding, and analysis bias was 
estimated for each study and can be found in Table 10.  The Green RCT used adequate 
randomization and concealment allocation, through simple computer randomization, leaving 
minimal risk for selection bias.  The groups were very similar at baseline in all measured 
characteristics, including sex, age, skin phenotype, sun exposure, sunburns, nevi, and previous 
history of skin cancer.  The dermatologist and dermatopathologists were masked, but the 
participants were not.  Masking the participant in this type of trial is not an option, because the 
use of a placebo was deemed unethical.  The nonmasking of participants introduced a risk for 
measurement bias if patients misreported sunscreen use based on knowledge of treatment 
allocation.  To help control for this possibility, investigators conducted sunscreen bottle weights 
to improve measurement of compliance in the treatment group.  Knowledge of treatment group 
could affect the measurement of exposure (sunscreen use), but should not have an effect on 
the measure of the outcome (melanoma).  This is likely to bias the results towards the null, as 
participants in the control group might underreport sunscreen use if they know they are in the 
non-treatment group and participants might over-report use if they know they are in the 
treatment group.   
There was only 1 drop out in each group, but a significant number of participants were 
passive participants at the start of follow-up (124 in the treatment group and 124 in the control 
group).  Another 190 participants in the treatment group and 180 in the control group became 
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passive participants during the follow-up period, introducing a risk for measurement bias of the 
exposure during follow-up.  We are not given information on potential differences between 
active and passive participants.  Melanoma outcome data was collected for all active and 
passive participants and cross checked with the national cancer registry, limiting the risk of 
measurement bias of the outcome.  There is significant discrepancy in the diagnoses of 
melanoma among pathologists.32  This was addressed by having two expert 
dermatopathologists, masked to sunscreen group allocation, review all melanoma diagnoses.   
There is minimal risk of confounding, as groups were similar at baseline due to 
randomization.  Melanoma was a secondary outcome for this trial, originally designed to assess 
squamous cell carcinoma and basal cell carcinoma.  Overall, the main risk of bias comes from 
unmasked participants and melanoma being a secondary outcome.  The study was given an 
internal validity quality rating of good; the results can be found in Tables 10 and 12.   
In the case-control study by Lazovich, a higher number of cases than controls 
participated in the survey and interview (84% of cases and 69% of controls).  There may be a 
difference between those who chose to participate and those who did not, but we are not given 
any information on eligible participants that chose not to participate, introducing a risk of 
selection bias.   
This study collected detailed information on sunscreen use and sun exposure in each 
decade of life.  This is superior to many case-control studies on this topic, which only use one 
question about sunscreen use to categorize participants.  However, the survey used in the study 
is not validated and there is risk of recall bias with self-reported sunscreen use.  The study also 
did not prevent knowledge of primary exposure influencing case ascertainment.  The controls 
were randomly selected from the state drivers license registry, which is not representative of the 
source population for the cases who were obtained from the state cancer registry.  There is also 
a risk of bias in the measurement of the outcome, as melanoma was diagnosed by many 
different pathologists.   
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The cases and controls were matched based on age and gender.  Income, education, 
skin phenotype, nevi number, family history, sunburns, indoor tanning, and sun exposure were 
controlled for during analysis.  There is a risk for analysis bias in this study, as they evaluated a 
large number of outcomes and had only one significant finding.  This could be due to chance, 
given the large number of analyses conducted.  This study was given an internal validity quality 
rating of fair;  see Tables 10, 11, and 12 for details.  A summary of the quality rating for each 
study using the 3 quality rating scales and an overall quality rating can be found in Table 15.   
Results of Individual Studies: 
The RCT by Green found a borderline significant HR of 0.50 (95% CI: 0.24 -1.02) for all 
melanoma and sunscreen use.52  When considering only invasive melanoma, the hazard ratio 
decreased to 0.27 (95% CI: 0.08 - 0.97).  Thirty-six total primary melanomas occurred during 
the study: 11 participants in the sunscreen group and 22 participants in the control group.  The 
average thickness of melanoma was 0.53 mm in the sunscreen group, versus 1.2 mm in the 
control group (p = 0.08). Eleven percent of the participants died during the study: 87 in the 
sunscreen group and 86 in the control group.  There was only one death due to melanoma that 
was diagnosed in 1978.  A summary of the main results can be found in Table 13.  
The Lazovich case-control study also found a decreased risk of melanoma with regular 
sunscreen use, defined as sunscreen use when not specifically engaging in an outdoor activity.  
The adjusted OR for regular use versus never use was 0.44 (95% CI: 0.23 - 0.86).53  The study 
also found a significant adjusted OR for optimal use of other sun protection methods (wearing a 
hat, long-sleeved shirt, or staying in the shade) versus never or rare use (OR: 0.59 [95% CI: 
0.44 -0.78]).  There was a possible trend of decreased melanoma risk with increasing use of 
SPF 15 or higher (OR: 0.83 [95% CI 0.62-1.12], p = 0.03).  All other variations of sunscreen use 
were not associated with melanoma risk, including use during outdoor actives (p = 0.59), 
thickness of application (p = 0.95), amount of skin covered (p = 0.66), and reapplication 
frequency (p = 0.71).  The main results from the study can be found in Table 14.  
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Synthesis of Results:  
  We were not able to perform a quantitative review given the different study designs and 
populations of the included studies.  Both included studies found a decreased risk of melanoma 
with regular sunscreen use in adults.  A summary of the main results can be found in Table 16.  
The Lazovich studies found no effect of other types of sunscreen use and the Green RCT trial 
was only designed to evaluate regular sunscreen use.  Neither study evaluated the use of 
sunscreen to prevent morbidity and mortality from melanoma.   
Neither study evaluated harms associated with sunscreen use, a significant limitation to 
fully quantifying the net benefit of sunscreen use.  Potential harms associated with sunscreen 
use include allergic reactions, skin irritation, decreased vitamin D synthesis, and psychological 
harm.    
Strength of Evidence:  
 We rated the overall strength of the evidence using the methods of the USPSTF.49  First 
we estimated the certainty of the evidence to be low based on the six key questions developed 
by the USPSTF.  A prospective cohort study or a RCT with longer follow up would be ideal for 
evaluating the effect of sunscreen use on melanoma, given the long duration from exposure to 
development of disease, low incidence of melanoma, and difficulty of exposure measurement in 
retrospective studies.  Case-control studies often over-estimate the effect of an intervention.   
The Green RCT was only designed to evaluate daily sunscreen use and does not 
evaluate long-term use or use to prevent intermittent sun exposure.  The Green RCT was given 
a good internal validity rating and the case-control study received a fair quality rating.  The 
Green study had poor precision due to the wide confidence intervals and small numbers with 
only 36 diagnosed melanomas.  Even so, the Green RCT received a higher quality rating than 
any study published on this topic in the past.   
Both studies were given an external validity rating of fair.  Both were single center 
studies conducted in one state.  The studies included people age 25 to 59 or 75; therefore, they 
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are only generalizable to adult populations.  The studies did not limit participants based on skin 
phenotype, but a limited number of participants had an olive/brown skin type (only 6 - 7% in the 
Green RCT).52  Australia has a much higher incidence of melanoma than the U.S., which limits 
its generalizability to U.S. populations. Minnesota also has a higher incidence of melanoma than 
other parts of the U.S.54  Both studies only evaluated sunscreen with an SPF of 15 or greater. 
Therefore, we conclude that these studies are only generalizable to the U.S. Caucasian 
screening population age 25 to 60, who use sunscreen with and SPF 15 or higher and 
UVA/UVB protection.   
The evidence is based on only two studies of 3889 participants.  Given the low incidence 
of melanoma, this is not a very large sample size.  There have been many studies published 
previously on this topic, but these studies were limited by uncontrolled confounding and 
conflicting results.  Both included studies found a reduced risk of melanoma associated with 
daily sunscreen use.  The HR was only significant in the Green RCT when considering invasive 
melanoma, but melanoma was a secondary outcome.  The Green RCT also had wide 
confidence intervals leading to low precision.  The case-control study found evidence of a 
possible trend of decreased melanoma risk with increasing use of SPF 15 or higher.  The case-
control study found no effect of other types of sunscreen use and the RCT was not designed to 
evaluate other types of sunscreen use.  Overall, we judged the certainty of the evidence as low 
for regular sunscreen use and other types of sunscreen use.  The studies found consistent 
results for daily sunscreen use and were of good to fair quality, but the evidence was limited by 
the precision, number, and size of included studies and fair generalizability.   
  We estimated the magnitude of the evidence for daily sunscreen use in the general U.S. 
population to be insufficient.  An outcomes table was made using the hazard ratio (HR: 0.50) 
from the Green RCT and the incidence of melanoma in the U.S. (see Table 17). We assumed 
an unchanging incidence of 21 cases per 100,000 people, based on current U.S. statistics.54  
The table has limited utility, because we have no information on mortality or harms.  We 
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considered estimating a change in mortality from the incidence data using the percentage of 
patients with melanoma that die in the U.S.  This estimation would be completely hypothetical 
and not based on study data, which limits its utility.   The table does show a small reduction in 
melanoma incidence with daily sunscreen use.  Logically, a decrease in melanoma incidence 
should lead to a decrease in mortality, but this is not proven.  Possible but poorly studied harms 
include skin irritation, allergic reactions, low vitamin D, and psychological harm.  Therefore, we 
gave daily sunscreen use a magnitude rating of insufficient.  Overall, daily sunscreen use was 
given a grade of insufficient, and other types of sunscreen use were also given a grade of 
insufficient.  
Table 9:  Internal Validity of Systematic Reviews USPSTF criteria: (* to *** good to poor) 
Study 
Reference 
Focused 
question  
Description 
of 
methodology 
Rigorousness 
of Literature 
review 
Standard 
Appraisal 
of included 
studies 
Validity of 
conclusions 
Recency 
and 
Relevance 
Kutting 
201150 
 
Excluded 
due to 
poor 
quality 
**  
“How effective 
are the 
recommended 
strategies for 
prevention of 
occupationally 
induced skin 
cancer?” 
*** 
Describe the 
benefits of a 
SR in the 
methods 
section, but 
not their 
methods.  
 
*** 
 Medline and 
Cochrane.  No 
flow diagram 
or inclusion/ 
exclusion 
criteria  
 
*** 
No. Report 
data from 
included 
studies but 
no 
appraisal of 
internal or 
external 
validity. 
 *** 
Used studies 
in final 
conclusions 
not in the 
SR.  
 
***  
Recent but 
the 
included 
studies do 
not 
address 
our key 
question.   
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Table 10: Internal Validity of Included Studies using USPSTF Criteria (* to *** low risk of bias 
to high risk of bias) 
Study  Selection bias Measurement 
Bias  
Confounding Analysis Bias Overall 
Rating of 
Internal 
Validity 
Green 
201152 
*  
Computer 
randomization 
 
*1/2  
Patients were 
not blinded.    
 
*  
Groups 
comparable 
at baseline 
 
**  
Melanoma was 
a secondary 
outcome.  
Good 
Lazovich 
201153 
**  
Uneven rates 
of participation 
between 
eligible cases 
and controls 
**  
Exposure 
measures not 
validated 
 
*1/2  
Matched age 
and gender.  
Adjusted for 
main 
confounders.  
 
**  
Most of the 
results were 
null.  One 
significant 
finding could 
be due to 
chance.  
Fair 
Vranova 
201251 
 
Excluded 
due to poor 
quality 
***  
Controls from 
different 
population.  
Controls not 
randomly 
selected. 9% 
of cases had a 
previous 
history of 
melanoma.  
***  
Exposure 
measures not 
validated. 
Self-survey. 
Asked only 
ever, 
occasional, 
routine 
sunscreen 
use 
** 
 Matched for 
some main 
confounders.  
Ages 
different.  
***  
Compared 
cases to young 
controls. Very 
different ages.  
 
Poor 
 
 
Table 11: Newcastle-Ottawa Quality Assessment Scale Case Control Studies 
Study Selection (****)  Comparability (**)  Exposure (***)  Overall (9) 
Lazovich 201153 *** 
Not all eligible 
cases 
participated. 
(only 84%)  
 
** 
Controlled for sun 
exposure and skin 
phenotype 
* 
Interview not 
blinded to 
case/control 
status. 
Response rate 
different in 
cases and 
controls.  
6/9 
Vranova 201251 * 
No independent 
validation of 
* 
Controlled for sun 
exposure. Ages 
* 
Interview not 
blinded to 
3/9 
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cases. Not all 
eligible cases 
participated. Did 
not exclude prior 
h/o melanoma.  
very different.  case/control 
status. 
Response rate 
different in 
cases and 
controls. 
 
Table 12: NICE Methodology Checklist 
Case-Control 
Studies 
Selection of 
Participants 
Assessment Confounding 
Factors 
Statistical 
Analysis (have 
CI been 
provided)  
Lazovich 201153 Adequately 
addressed to 
well covered 
Poorly 
Addressed 
Adequately 
covered  
Yes (only one 
significant result 
of many 
analyzed)  
Vranova 201251 Poorly 
Addressed 
Poorly 
Addressed 
Poorly 
Addressed (age)  
Yes 
Randomized, 
Controlled 
Trials 
Selection Bias Performance 
Bias 
Attrition Bias Detection Bias 
Green 201152 Low risk of bias 
(positive answer 
to all criteria)  
Low to medium 
risk of bias 
(1 negative 
answer)  
Low to medium  
risk of bias 
(1 unclear 
answer)  
Unclear/unknown 
risk of bias 
(2 unclear 
answers)  
Systematic 
review and 
Meta-analysis  
Internal Validity Overall 
Assessment 
(++,+,-) how well 
was the study 
done to minimize 
bias?  
Included Study 
types 
How does this 
review help to 
answer your 
key question?  
 
Kutting 201150 Poorly 
Addressed 
__ Case-control and 
cohort studies 
The included 
studies do not 
address our key 
question.  
Information 
included on our 
key question is 
from a critical 
review not a SR.   
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Table 13: Evidence Table Randomized, Controlled Trials24 
Study 
Reference 
Study Design 
Location  
Recruitment 
Strategy  
Participant 
inclusion/ 
exclusion 
criteria  
 
Baseline 
demographics  
 
Intervention(s) 
evaluated  
Follow-up  
 
Main outcome 
measure(s)  
 
Green 201152 Study Design: 
RCT 
Location:  
Queensland, 
Australia  
Recruitment 
Strategy: 
Randomly 
selected from the 
election roll.  
Inclusion: Must 
return initial 
survey.  
Exclusion: None 
N=1,621 (1339 
active) 
Mean age: 
55% <50 
Female: 56% 
Race: Not 
reported 
SES: Not 
reported 
Skin type: 
55% Tx and 
56% Cx fair 
Duration:  4 
years 
Format: Applied 
to head neck 
arms hands every 
morning and 
reapplication 
advised after 
sweating, 
bathing, or long 
sun exposure 
Intensity: SPF 
16 (UVA and 
UVB protection) 
Delivery: By the 
patient 
10 years 
follow up. 
Some 
participates 
passive. 
Tx: 315 of 
812. Cx: 
308 of 809 
Measure: HR 
Results:  
Routine use vs. 
Discretionary 
use  
All melanoma: 
(HR: 0.50 [95% 
CI: 0.24 – 1.02]) 
 
11 melanomas in 
Tx group and 22 
in Cx group 
 
Study Reference Other positive outcome 
measurements  
Adverse 
events 
Comments 
Green 201152 Invasive Melanoma: (HR: 
0.27 [95% CI: 0.08 to 0.97]) 
Pre-invasive 
melanoma:(HR: 0.73 [95% 
CI: 0.29 to 1.81]) 
Mortality: 11% total. 87 Tx 
and 86 Cx.1 from melanoma.   
Not reported Melanoma was a secondary 
outcome. Did not exclude 
people with a previous history 
of melanoma.  Many 
participants passive during 
follow up.  
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Table 14: Evidence Table Case Control Studies24 
Study 
Reference 
Study 
Design  
Location  
Population 
Participant Inclusion/ Exclusion  Baseline Demographics Measurement of 
exposure 
(sunscreen use)  
Lazovich 
201153 
Study 
Design:  
Case-
Control 
Location: 
Minnesota, 
U.S. 
Cases:  
Selection: State Cancer Registry  
Eligibility Criteria: Diagnosed between 
2004 and 2007 with invasive cutaneous 
melanoma. Age 25-59.  
Controls: 
Selection: Randomly selected from state 
driver license list 
Eligibility Criteria: Matched by age and 
gender. Live in MN, never diagnosed with 
melanoma 
Cases:  
n= 1167  
Controls: n=1101  
 
Age: Cx n= 447 age 50-59 
Sex: Not reported 
Skin type: Phenotypic risk index. 
Cases 53% high. Controls: 62% high.  
Asked about 
sunscreen use 
and sun exposure 
in each decade of 
life by telephone 
interview. 
(obtained 
information on 
97% of cases and 
controls)  
Vranova 
201251 
 
Excluded 
due to poor 
quality 
Study 
Design:  
Case-
Control 
Location: 
Praque, 
Czech 
Republic.   
 
Cases:  
Selection: Diagnosed with cutaneous 
melanoma at Kraloveske Vinohrady 
University 
Eligibility Criteria: Not reported.  
Controls: 
Young:  
Selection: Randomly selected 1st year 
students at Charles University and faculty 
from Czech Technical University.   
Eligibility Criteria: Excluded if they had 
active melanoma or were non-Caucasian. 
Old:  
Selection: Responded to notice at 
Charles Hospital in Prague.  
Eligibility Criteria: Excluded if they had 
active melanoma or were non-Caucasian.  
 
Cases: n= 216 
Controls: n= 762  
(460 young and 302 old)  
 
Age:  
Cases: 53.6 
Young Cx: 19.9 
Old Cx: 51.1 
% Female:  
Cases: 43% 
Young Cx: 65% 
Old: 62% 
Skin type:  
Skin classified at always turns red, 
sometimes turns brown.  
Cases: 62% 
Young Cx: 23% 
Old Cx: 32% 
19 question self-
administered 
survey.   
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Study 
Reference  
Confounders 
Considered  
Measurement of Sun Exposure Measurement of Sunscreen use Measurement 
of Sunburn 
Comments 
Lazovich 
201153 
Gender, age, 
income, 
education, skin 
phenotype, 
number of nevi, 
family history, 
sunburns, indoor 
tanning, sun 
exposure 
 
Total sun exposure: High sun exposure 
Cases 41%, Controls 41% 
Total recreational sun exposure: High 
outdoor activity Cases: 44% Controls: 44% 
Total years in outdoor jobs: Not reported  
Number of vacations: Not reported 
 
Protective Clothing: Cases: Rarely/never 
26% Frequent 19% Controls: Rarely/never 
21% Frequent: 25% 
 
Asked about sunscreen use during 
different outdoor activities (time 
spent at the beach or pool, 
sunbathing, boating or waterskiing, 
fishing, playing or coaching outdoor 
team sports, walking, hiking or 
jogging, biking, roller skating or 
rollerblading, golfing, playing 
tennis, playing outside, gardening 
or performing outdoor chores, and 
winter sports.) Including frequency 
of use of SPF >15, thickness, 
amount of exposed skin covered, 
reapplication after > 2hrs, and 
frequency of sunscreen use when 
not specifically doing a sun related 
activity. Averaged use within each 
decade and across all decades. 
Reported they 
collected this 
information but 
it is not 
reported.   
Only included 
sunscreen SPF 
>15.  Type of UV 
protection 
unknown.  
Vranova 
201251 
 
Excluded 
due to 
poor 
quality 
Skin phenotype, 
history of skin 
cancer, number 
of  nevi, 
immunosuppressi
on, sunburns, 
sun exposure 
Total sun exposure: Reported all day sun 
exposure  
Cases: 67%  
Young Cx: 70% Old Cx: 32% 
Total recreational sun exposure:  Active 
Sunbathing or sports Cases: 69% Young Cx: 
93% Old Cx: 84% 
Total years in outdoor jobs: Not reported  
Number of vacations: Seaside Vacations 
never: Cases:  5.6% Young Cx 5.2 Old Cx: 
8.0%. Mountains Vacations Never: Cases: 
10.2% Young Cx: 4.8% Old Cx: 17.2% 
Asked about sunscreen use in 
childhood and adulthood. Never, 
occasionally, or regularly.  
(Regularly defined as more than 5 
times per sun tanning). SPF, 
thickness, and location applied not 
specified. 
  
Reported No 
sunburns in 
childhood: 
Cases  8.3% 
Young Cx: 
63% Old Cx: 
33% 
Compare patients 
of different ages, 
very different 
baseline 
characteristics. 
Type of UV 
protection 
unknown.   
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Table 15 Overall Internal Validity of Included Studies  
Study USPSTF NICE Newcastle-
Ottawa  
Overall 
Internal 
Validity  
External 
Validity  
Green 201152 Good (I) Low/medium 
risk of bias 
NA Good  Fair  
 
Kutting 
201050 
 
Poor (III) __ NA Poor NA 
Lazovich 
201153 
Fair  (II-2)  Adequate 6/9 Fair Fair 
Vranova 
201251 
 
Poor (II-2) Poor 3/9 Poor NA 
 
Table 16: Summary Characteristics of Included Studies 
Study Design 
 
Population Routine use 
(HR or 
OR[95%CI]) 
Adjustments reported 
Green 
201152 
Randomized 
control trial 
Queensland, 
Australia.  
Tx: 812, Cx: 809 
56% female, 55% 
<50 
vs. Discretionary 
use  
(HR: 0.50 [95% 
CI: 0.24 – 1.02]) 
 
None. Groups comparable 
at baseline 
 
Kutting 
201050 
Excluded 
due to 
poor 
quality 
Systematic 
review 
Outdoor workers 
 
NA NA 
Lazovich 
201153 
Case-control  Minnesota, US 
Case: 1167 Cx: 
1101.  
 
Vs. Never use 
(OR: 0.44 [95% 
CI: 0.23- 0.86]) 
 
Gender, age, income, 
education, skin phenotype, 
number of nevi, family 
history, sunburns, indoor 
tanning, sun exposure 
Vranova 
201251 
Excluded 
due to 
poor 
quality 
Case-control  Praque, Czech 
Republic.  Case: 
216 Control: 762 
 
Vs. 
Occasionally use 
(OR: 0.21 [95% 
CI: 0.058-0.74]) 
  
 
Phenotype, history of skin 
cancer, number of  nevi, 
immunosuppression, 
sunburns, sun exposure 
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Table 17: Outcomes Table for Daily Sunscreen Use Over 15 years in the general U.S. 
Caucasian population age 25 to 60 
 Daily Sunscreen Use 
(SPF 15 or higher) 
Discretionary Sunscreen 
Use 
Incidence of Melanoma  158/100,000 315/100,000 
Mortality from Melanoma ?? ?? 
Harms 
 
??  
Not assessed 
??  
 
 
Error! Reference source not found. 
Figure 1: Flow Diagram of Search 
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Discussion 
Summary of the Evidence  
The USPSTF review conducted in 2008 found insufficient evidence to recommend for or 
against the use of sunscreen to prevent melanoma.  This recommendation was based on 5 fair 
quality observational studies with significant uncontrolled confounding.24  The results of this 
review found insufficient evidence on the effect of daily sunscreen use on risk of melanoma, 
resulting in a I recommendation. The review also found insufficient evidence to recommend for or 
against other types of sunscreen use.  A summary of the findings are available in Table 18.   
We found one fair quality case-control study and one good quality RCT evaluating the 
relationship between sunscreen use and melanoma.  The Green RCT is a landmark study, the 
first RCT published on this topic, which found decreased melanoma risk with daily sunscreen 
use.  It is the first study published on this topic with adequate design to control for important 
confounders like sun exposure and skin phenotype.  The Green RCT was designed to evaluate 
the ability of sunscreen to prevent chronic sun exposure, as participants applied sunscreen daily.  
This finding is surprising as chronic sun exposure is not associated with melanoma risk in 
observational studies.23  The study does not address the ability of sunscreen to prevent 
intermittent, severe sun exposure, which is more highly associated with melanoma risk.23  The 
study did not have long enough follow-up to evaluate the effect of sunscreen use on morbidity 
and mortality from melanoma.  The case-control study evaluated several different types of 
sunscreen use, including sunscreen use when not engaging in a sun related activity (regular 
use), use during outdoor activities, thickness of application, location of skin covered, 
reapplication frequency, and SPF used.  The study had a superior measure of sun exposure and 
sunscreen use than previous observational studies, as it evaluated sun habits in each decade of 
life.  It also obtained information about SPF, location applied, frequency, and reapplication of 
sunscreen.  The study found a decreased risk of melanoma with regular sunscreen use and a 
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possible trend of decreased melanoma risk with increasing use of SPF 15 or higher.  All other 
types of sunscreen use were not associated with melanoma risk.   
Therefore, we concluded there is moderate evidence for a small effect of daily sunscreen 
use on melanoma risk, based on one good quality RCT and one fair quality case-control study.  
There is insufficient evidence for other types of sunscreen use, based on one fair quality case-
control study.   
Table 18: Summary of the Evidence 
# of 
Studies 
Design Limitations Consistency Applicability Overall  
Grade 
Summary 
of the 
Findings 
2 1 RCT 
 
1 Case- 
control 
No 
assessment 
of harms.  Did 
not assess 
morbidity, 
mortality, or 
quality of life.  
Melanoma 
was a 
secondary 
outcome in 
RCT. Crude 
measure of 
sun exposure. 
Case-control 
studies 
subject to 
recall bias.  
High. Both 
found 
decreased 
melanoma 
risk with 
regular 
sunscreen 
use.  No 
effect of 
other types 
of sunscreen 
use.   
Caucasian 
populations.  
Age 25 to 60 
only. Proper 
daily 
sunscreen 
use is time 
consuming 
and 
expensive.  
Routine 
sunscreen 
use: I 
 
Other 
types of 
sunscreen 
use: I 
Routine 
sunscreen 
use may 
protect 
against the 
development 
of 
melanoma in 
Caucasians 
age 25 to 
60.   
 
Limitations: 
There are several limitations of this review, including the literature search, quality rating of 
included articles, and the literature itself.  We only searched one major database, MEDLINE, 
given the significant number of results returned and time constraints.  We consulted with a health 
science librarian in the development of our search strategy, but there is still a risk we did not 
identify all potential articles.  We used the quality rating system developed by the USPSTF for 
their 2008 review, which combined 3 different quality rating checklists.  This resulted in some 
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decision making on our part about how to combine the 3 rating systems to determine a final 
quality grade for each study.  There is also a risk for publication bias.  We searched the U.S. 
government clinical trials website to limit this bias, given the recency of our search timeline, but 
there is still significant risk for publication bias.   
The literature on this topic has many significant limitations.  No studies on this topic have 
evaluated the direct effect of sunscreen use on morbidity and mortality, the most clinically 
important outcome.  The studies in this review did not assess harms associated with sunscreen 
use.  We only found two studies of high enough quality to be included, limiting our sample size.  
Observational studies on this topic are limited by difficult to control confounding, as the main 
determinates of sunscreen use are also risk factors for melanoma.  Sun exposure and sunscreen 
use are also very difficult exposures to measure; the included case-control study tried to improve 
this measure by determining sun exposure and sunscreen habits in each decade of life.  Recall 
bias is also a significant problem in retrospective, observational studies.  Melanoma was a 
secondary outcome in the RCT, and participants were not blinded to treatment group allocation, 
leaving a risk for measurement bias.  The studies also considered all types of melanoma 
together, even though there is emerging evidence that risk factors for melanoma are different 
based on subtype and anatomic location.55  The studies included in this review also had limited 
external validity, as they were single state studies, conducted in areas with a higher incidence of 
melanoma than the general U.S. population.   
Future Research:  
 There are many potential avenues for future research on the relationship between 
sunscreen use and melanoma.  The results of this review suggest an association between daily 
sunscreen use and melanoma, but there are significant gaps in our knowledge about other types 
of sunscreen use.  A well-deigned RCT or prospective, cohort study is needed to understand the 
relationship between sunscreen use in childhood and adolescence and melanoma risk, as 
severe intermittent sun exposure during childhood is more highly associated with melanoma than 
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chronic sun exposure.23  Ideally, an RCT of sunscreen use during childhood and adolescence 
with long term follow-up could help us to understand the relationship between sunscreen use and 
melanoma morbidity and mortality.  For observational studies on this topic to be useful, we need 
improved, valid, reliable, and consistent measures of sunscreen use and sun exposure.  Future 
research also needs to differentiate melanoma by subtype and anatomic location to fully 
understand the complex relationship between sun exposure and melanoma.   
 There is also a large gap in the research on the harms associated with sunscreen use.  
More research is needed to determine if sunscreen use affects vitamin D levels and if the time 
and cost associated with daily sunscreen use is worthwhile.  If it is determined with increased 
certainty that daily sunscreen use is beneficial, we must learn the best way to educate and 
motive people to apply sunscreen correctly.  Uncertainties also exist in other areas of the 
relationship between sun exposure prevention and melanoma, including protective gear to avoid 
sun exposure and indoor tanning beds.   
Conclusions: 
The results of this systematic review suggest that regular sunscreen use can decrease 
the risk of melanoma in adult Caucasians.  There is only one good quality RCT and one fair 
quality case-control study to support this relationship, which was given a recommendation grade 
of I.  This review also found insufficient evidence to recommend for or against other types of 
sunscreen use.  Given the grade I recommendation, we do not believe the evidence is certain or 
substantial enough to recommend daily sunscreen use for all U.S. adult Caucasians.  Patients at 
high risk of melanoma should be presented the evidence on sunscreen use and other preventive 
methods and allowed to make a personal decision with their healthcare provider.   
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Appendix A: Definitions of Key terms revised from the USPSTF 2008 review24 
 
Melanoma: Cutaneous melanoma includes four major subtypes: superficial spreading, nodular, 
lentigo maligna, and acral lentiginous. For the purposes of this review, acral melanoma, as well 
as mucosal melanoma, ocular melanoma, and pre-pubertal melanoma (“childhood melanoma”), 
are excluded. 
Nevi: Benign pigmented spot on the skin, such as a mole, that is a cluster of melanocytes and 
supportive tissue. In contrast, dysplastic nevi, or atypical moles, are melanocytic lesions that can 
be precursors to melanoma. Dysplastic nevi are distinguished by histology; however, they may 
also have certain clinical characteristics (e.g., increased diameter, lack of pigment uniformity). 
Skin phenotype: Skin, hair, and eye color and skin type (i.e., ability to tan or burn that is 
genetically determined). A common measure of skin type is the Fitzpatrick Skin Type Scale.  
Sun exposure: Intermittent, chronic, or total exposure to ultraviolet light. Intermittent patterns of 
exposure are most often related to recreational activities, versus chronic or continuous patterns 
of exposure, which are related to occupational exposure. For the purposes of this review, studies 
that included only crude measures of sun exposure (e.g., place of residence or type of 
occupation) were excluded. 
Sunburn: Inflammation of the skin in response to ultraviolet light, manifested by painful 
erythema with or without blistering. 
Sunscreen or sunblock: Lotion with sun protection factor (SPF) 15 or higher that is used to 
protect against ultraviolet light, both UVA and UVB. Protection against UVA was added in 1989. 
SPF was introduced in 1978 and is reported when available. For the purposes of this review, sun 
tan lotions or oils were excluded. 
 
Appendix B: Abbreviations used in the review  
RCT: Randomized Controlled Trial 
HR: Hazard Ratio 
RR: Relative Risk 
OR: Odds Ratio 
CI: Confidence interval  
UVR: Ultra-Violet Radiation 
NICE: National Institute for Health and Clinical Excellence  
 
Appendix C: Fitzpatrick Skin Type21 
 
Fitzpatrick Skin Type:  Skin Color Reaction to sun exposure at 
the beginning of the 
summer  
Type I Extremely fair skin Always burns, never tans 
Type II Fair Skin Always burns, sometimes 
tans. 
Type III Medium Skin Sometimes burns, always 
tans. 
Type IV Olive Skin Rarely burns, always tans. 
Type V Moderately pigmented brown 
skin 
Never burns, always tans 
Type VI  Markedly pigmented black 
skin 
Never burns, always tans. 
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Appendix D: Sun Protection Factor Explained 
Sun Protection Factor refers to sunscreens’ ability to prevent exposure to UVB radiation.  An 
SPF of 15 protects against about 93% of UVB exposure while an SPF of 30 prevents 97% of 
UVB exposure.56 UVB protection is tested in the laboratories with a sunscreen thickness of 
2mg/cm2, in- vivo research shows that the SPF protection decreases with decreased thickness 
application and most sunscreen users only apply about ¼ of the recommended amount.38  There 
is no standardized measure for UVA protection.  The American Academy of Dermatology 
Recommends an SPF of 30 or greater applied 15-30 minutes before sun exposure to all 
exposure body areas.57 
 
Appendix E: Search Strategy 
1. Melanoma (84330)   
2. Skin cancer (128343) 
3. Sunscreen Agents (11722) 
4. 1 or 2 Melanoma or Skin cancer (183259) 
5. 3 and 4 Melanoma or Skin cancer and Sunscreen agents (1314) 
6. Limit 5 to 11/01/2008 to 03/08/2012 (261) 
 
Appendix F: Studies Excluded During Full Text Review 
Title Full Reference Reason  
Panel demands FDA 
action to address 
dramatic increases in 
skin cancer in United 
States 
Panel demands FDA action to address dramatic increases in skin 
cancer in United States. Dermatol Nurs. 2009 Jul-Aug;21(4):221. 
Study 
design/ 
publication 
type 
Early recognition and 
prevention of skin cancer 
Held, L;Eigentler, T K;Garbe, C;Germany;MMW Fortschritte der 
Medizin;MMW Fortschr Med. 2009 Sep 24;151(39):31-3. 
Non- 
English 
Sunscreens 
Kaimal, Sowmya;Abraham, Anil;Review;India;Indian journal of 
dermatology, venereology and leprology;Indian J Dermatol Venereol 
Leprol. 2011 Mar-Apr;77(2):238-43. 
Study 
design/ 
publication 
type 
Ultraviolet radiation and 
melanoma 
Kanavy, Holly E;Gerstenblith, Meg R;United States;Seminars in 
cutaneous medicine and surgery;Semin Cutan Med Surg. 2011 
Dec;30(4):222-8. 
Study 
design/ 
publication 
type 
Attitudes, knowledge and 
behaviors with regard to 
skin cancer: a literature 
review 
Keeney, Sinead;McKenna, Hugh;Fleming, Paul;McIlfatrick, 
Sonja;Review;Scotland;European journal of oncology nursing : the 
official journal of European Oncology Nursing Society;Eur J Oncol 
Nurs. 2009 Feb;13(1):29-35. Epub 2009 Jan 18. 
Outcome 
Skin cancer prevention in 
Canada. Preface 
Kerner, Jon F;Introductory;Research Support, Non-U.S. 
Gov't;Canada;Canadian journal of public health. Revue canadienne de 
sante publique;Can J Public Health. 2010 Jul-Aug;101(4):I3-4. 
Study 
design/ 
publication 
type 
Sunscreen prevention of 
melanoma in man and 
mouse 
Klug, Heather L P;Tooze, Janet A;Graff-Cherry, Cari;Anver, Miriam 
R;Noonan, Frances P;Fears, Thomas R;Tucker, Margaret A;De Fabo, 
Edward C;Merlino, Glenn;Letter;Research Support, N.I.H., 
Extramural;Research Support, N.I.H., Intramural;England;Pigment cell 
& melanoma research;Pigment Cell Melanoma Res. 2010 
Study 
design/ 
publication 
type 
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Dec;23(6):835-7. Epub 2010 Aug 20.  
Here comes the sun 
Knight, Claire;England;The journal of family health care;J Fam Health 
Care. 2011 Jul-Aug;21(4):12-3, 15. 
Study 
design/ 
publication 
type 
ACP journal club. 
Regular sunscreen use 
reduces invasive but not 
overall melanoma in 
white adults 
Lebwohl, Mark;Comment;United States;Annals of internal medicine;Ann 
Intern Med. 2011 May 17;154(10):JC5-12. 
Data 
reported in 
another 
article 
Sun protection and 
pediatricians: results of a 
survey 
Assathiany, R;Fay-Chatelard, F;Beauchet, A;Navel, M;Mahe, 
E;France;Archives de pediatrie : organe officiel de la Societe francaise 
de pediatrie;Arch Pediatr. 2010 Jun;17(6):908-9. 
Non- 
English 
Photoprotection with 
clothing and sunscreens 
Malbasa, C;Baron, E D;Review;Italy;Giornale italiano di dermatologia e 
venereologia : organo ufficiale, Societa italiana di dermatologia e 
sifilografia;G Ital Dermatol Venereol. 2010 Aug;145(4):509-14. 
Study 
design/ 
publication 
type 
Sun-protection behaviors 
of melanoma survivors 
Mayer, Deborah;Layman, Annah;Carlson, John;R03 CA136077-
02/CA/NCI NIH HHS/United States;R03CA136077/CA/NCI NIH 
HHS/United States;Letter;Research Support, N.I.H., Extramural;United 
States;Journal of the American Academy of 
Dermatology;Nihms278298;J Am Acad Dermatol. 2012 Jan;66(1):e9-
10. 
Population 
NICE recommends 
greater use of 
sunscreens at school and 
work to prevent skin 
cancer 
Mayor, Susan;News;England;BMJ (Clinical research ed.);BMJ. 2010 
Aug 26;341:c4641. doi: 10.1136/bmj.c4641. 
Study 
design/ 
publication 
type 
Risk factors in a cohort of 
patients with multiple 
primary melanoma 
McMeniman, Erin;De'Ambrosis, Kathryn;De'Ambrosis, 
Brian;Australia;The Australasian journal of dermatology;Australas J 
Dermatol. 2010 Nov;51(4):254-7. doi: 10.1111/j.1440-
0960.2010.00674.x. 
Study 
design/ 
publication 
type 
A potent activator of 
melanogenesis identified 
from small-molecule 
screening 
McNaughton, Brian R;Gareiss, Peter C;Jacobs, Stacey E;Fricke, Alex 
F;Scott, Glynis A;Miller, Benjamin L;T32AR007472/AR/NIAMS NIH 
HHS/United States;Research Support, N.I.H., 
Extramural;Germany;ChemMedChem;ChemMedChem. 2009 
Oct;4(10):1583-9. 
Intervention 
Synthetic aromatic 
compounds interfering 
with melanogenesis are 
responsible of the rising 
trend of malignant 
melanoma incidence 
Morpurgo, Giorgio;Babudri, Nora;Fioretti, Bernard;Franciolini, 
Fabio;Catacuzzeno, Luigi;United States;Medical hypotheses;Med 
Hypotheses. 2011 Mar;76(3):374-7. Epub 2010 Nov 20. 
Study 
design/ 
publication 
type 
Ultraviolet radiation and 
skin cancer 
Narayanan, Deevya L;Saladi, Rao N;Fox, Joshua L;Review;United 
States;International journal of dermatology;Int J Dermatol. 2010 
Sep;49(9):978-86. doi: 10.1111/j.1365-4632.2010.04474.x. 
Study 
design/ 
publication 
type 
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Sunscreen abuse for 
intentional sun exposure 
Autier, P;Review;England;The British journal of dermatology;Br J 
Dermatol. 2009 Nov;161 Suppl 3:40-5. 
Study 
design/ 
publication 
type 
Is sunscreen use for 
melanoma prevention 
valid for all sun exposure 
circumstances? 
Autier, Philippe;Boniol, Mathieu;Dore, Jean-
Francois;Comment;Letter;United States;Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology;J Clin 
Oncol. 2011 May 10;29(14):e425-6; author reply e427. Epub 2011 Apr 
4. 
Study 
design/ 
publication 
type 
Not all tanners are 
created equal: 
implications of tanning 
subtypes for skin cancer 
prevention 
Pagoto, Sherry L;Hillhouse, Joel;R21 CA109670-02/CA/NCI NIH 
HHS/United States;R21 CA116384-01A1/CA/NCI NIH HHS/United 
States;Comment;Editorial;United States;Archives of 
dermatology;Nihms334804;Arch Dermatol. 2008 Nov;144(11):1505-8. 
Outcome 
Epidemiological evidence 
that UVA radiation is 
involved in the genesis of 
cutaneous melanoma 
Autier, Philippe;Dore, Jean-Francois;Eggermont, Alexander M 
M;Coebergh, Jan W;Review;United States;Current opinion in 
oncology;Curr Opin Oncol. 2011 Mar;23(2):189-96. 
Study 
design/ 
publication 
type 
Sunscreen and 
melanoma: is our 
prevention message 
correct? 
Planta, Margaret B;United States;Journal of the American Board of 
Family Medicine : JABFM;J Am Board Fam Med. 2011 Nov;24(6):735-
9. 
Study 
design/ 
publication 
type 
Acute skin sun damage 
in children and its 
consequences in adults 
Pustisek, Nives;Sikanic-Dugic, Nives;Hirsl-Hecej, Vlasta;Domljan, 
Mislav Luka;Review;Croatia;Collegium antropologicum;Coll Antropol. 
2010 Apr;34 Suppl 2:233-7. 
Study 
design/ 
publication 
type 
Photoprotection and 
children: why and how? 
Puzenat, E;France;Archives de pediatrie : organe officiel de la Societe 
francaise de pediatrie;Arch Pediatr. 2010 Jun;17(6):914-5. 
Non- 
English 
Protecting yourself 
against melanoma 
United States;The Johns Hopkins medical letter health after 50;Johns 
Hopkins Med Lett Health After 50. 2009 Jul;21(5):6-7. 
Study 
design/ 
publication 
type 
Trends in melanoma 
incidence among 
children: possible 
influence of sun-
protection programs 
Baade, Peter D;Green, Adele C;Smithers, Bernard Mark;Aitken, Joanne 
F;Editorial;England;Expert review of anticancer therapy;Expert Rev 
Anticancer Ther. 2011 May;11(5):661-4. 
Study 
design/ 
publication 
type 
The lower incidence of 
melanoma in women 
may be related to 
increased preventative 
behaviors 
Reuter, Nathaniel P;Bower, Matthew;Scoggins, Charles R;Martin, 
Robert C G;McMasters, Kelly M;Chagpar, Anees B;United 
States;American journal of surgery;Am J Surg. 2010 Dec;200(6):765-8, 
discussion 768-9. 
Outcome 
Another duel in the sun: 
weighing the balances 
between sun protection, 
tanning beds, and 
malignant melanoma 
Roberts, Daniel J;Hornung, Carlton A;Polk, Hiram C Jr;Comparative 
Study;Research Support, Non-U.S. Gov't;United States;Clinical 
pediatrics;Clin Pediatr (Phila). 2009 Jul;48(6):614-22. Epub 2009 Mar 
12. 
Study 
design/ 
publication 
type 
Prevention of melanoma 
with regular sunscreen 
Robinson, June K;Bigby, Michael;United States;JAMA : the journal of 
the American Medical Association;JAMA. 2011 Jul 20;306(3):302-3. 
Study 
design/ 
44 
 
 
use Epub 2011 Jun 28. publication 
type 
Skin cancers and other 
cutaneous diseases in 
renal transplant 
recipients: a single Italian 
center observational 
study 
Savoia, Paola;Stroppiana, Elena;Cavaliere, Giovanni;Osella-Abate, 
Simona;Mezza, Elisabetta;Segoloni, Giuseppe Paolo;Bernengo, Maria 
Grazia;France;European journal of dermatology : EJD;Eur J Dermatol. 
2011 Mar-Apr;21(2):242-7. 
Non- 
English 
The determinants of 
periorbital skin ageing in 
participants of a 
melanoma case-control 
study in the U.K 
Suppa, M;Elliott, F;Mikeljevic, J S;Mukasa, Y;Chan, M;Leake, 
S;Karpavicius, B;Haynes, S;Bakker, E;Peris, K;Barrett, J H;Bishop, D 
T;Newton Bishop, J A;C588 ⁄A10589/Cancer Research UK/United 
Kingdom;C588 ⁄A4994/Cancer Research UK/United Kingdom;C8216 
⁄A6129/Cancer Research UK/United Kingdom;R01 CA083115-
05/CA/NCI NIH HHS/United States;R01 CA83115/CA/NCI NIH 
HHS/United States;Research Support, N.I.H., Extramural;Research 
Support, Non-U.S. Gov't;England;The British journal of 
dermatology;Nihms313394;Br J Dermatol. 2011 Nov;165(5):1011-21. 
doi: 10.1111/j.1365-2133.2011.10536.x. 
Outcome 
Organ transplant 
recipients and skin 
cancer: assessment of 
risk factors with focus on 
sun exposure 
Terhorst, D;Drecoll, U;Stockfleth, E;Ulrich, C;England;The British 
journal of dermatology;Br J Dermatol. 2009 Nov;161 Suppl 3:85-9. 
Outcome 
Sunscreen use in adults 
is beneficial in preventing 
melanoma 
Barton, Mary Kay;United States;CA: a cancer journal for clinicians;CA 
Cancer J Clin. 2011 May-Jun;61(3):137-8. Epub 2011 May 1. 
Study 
design/ 
publication 
type 
[Update on 
photoprotection in 
children] 
Valdivielso-Ramos, M;Herranz, J M;English 
Abstract;Review;Spain;Anales de pediatria (Barcelona, Spain : 
2003);An Pediatr (Barc). 2010 Apr;72(4):282.e1-9. Epub 2010 Jan 6. 
Non- 
English 
Lentigo maligna 
Van der Waal, R I F;Case Reports;Netherlands;Nederlands tijdschrift 
voor tandheelkunde;Ned Tijdschr Tandheelkd. 2011 Nov;118(11):531. 
Non- 
English 
Photoprotection: a review 
of the current and future 
technologies 
Wang, Steven Q;Balagula, Yevgeniy;Osterwalder, 
Uli;Review;Denmark;Dermatologic therapy;Dermatol Ther. 2010 Jan-
Feb;23(1):31-47. 
Study 
design/ 
publication 
type 
Sun behavior patterns 
and perception of illness 
among melanoma 
patients 
Journal of the European Academy of Dermatology and Venereology : 
JEADV;J Eur Acad Dermatol Venereol. 2011 Jun 21. doi: 
10.1111/j.1468-3083.2011.04154.x. 
Population 
Take cover: shielding 
patients from skin cancer 
Zoller, Santrina;United States;Advance for NPs & PAs;Adv NPs PAs. 
2011 Jun;2(6):28-31. 
Study 
design/ 
publication 
type 
45 
 
 
Measuring sunscreens' 
ability to protect against 
skin cancer. 
Effectiveness goes 
beyond SPF rating 
AVMA Group Health;Life Insurance Trust;News;United States;Journal 
of the American Veterinary Medical Association;J Am Vet Med Assoc. 
2009 Jul 15;235(2):137-8. 
Study 
design/ 
publication 
type 
A prospective 
randomized controlled 
trial indicates that 
sunscreen use reduced 
the risk of developing 
melanoma 
Bigby, Michael;Kim, Caroline C;Comment;United States;Archives of 
dermatology;Arch Dermatol. 2011 Jul;147(7):853-4. 
Data 
reported in 
another 
article 
Sunscreen use for skin 
cancer prevention 
Bouknight, Patricia;Bowling, Andrew;Kovach, Fran E;Review;United 
States;American family physician;Am Fam Physician. 2010 Oct 
15;82(8):989-90. 
Study 
design/ 
publication 
type 
Skin care behaviors 
among melanoma 
survivors 
Psycho-oncology;Psychooncology. 2011 Jul 21. doi: 10.1002/pon.2017. 
Study 
design/ 
publication 
type 
Behaviors associated 
with ultraviolet radiation 
exposure in a cohort of 
adult survivors of 
childhood and adolescent 
cancer: a report from the 
Childhood Cancer 
Survivor Study 
Buchanan, Natasha;Leisenring, Wendy;Mitby, Pauline A;Meadows, 
Anna T;Robison, Leslie L;Hudson, Melissa M;Mertens, Ann C;U24 
CA055727-14/CA/NCI NIH HHS/United States;U24 CA55727/CA/NCI 
NIH HHS/United States;Research Support, N.I.H., Extramural;United 
States;Cancer;Nihms124352;Cancer. 2009 Sep 15;115(18 
Suppl):4374-84. 
Outcome 
Current sunscreen 
controversies: a critical 
review 
Burnett, Mark E;Wang, Steven Q;Review;Denmark;Photodermatology, 
photoimmunology & photomedicine;Photodermatol Photoimmunol 
Photomed. 2011 Apr;27(2):58-67. doi: 10.1111/j.1600-
0781.2011.00557.x. 
Study 
design/ 
publication 
type 
Do sunscreens have a 
role in preventing skin 
cancer? 
Review;England;Drug and therapeutics bulletin;Drug Ther Bull. 2011 
Jun;49(6):69-72. 
Study 
design/ 
publication 
type 
Sun exposure and 
children: what do they 
know? An observational 
study in an Italian school 
de Giorgi, Vincenzo;Gori, Alessia;Grazzini, Marta;Janowska, 
Agata;Rossari, Susanna;Papi, Federica;Alfaioli, Barbara;Savarese, 
Imma;Lotti, Torello;Comparative Study;Letter;United States;Preventive 
medicine;Prev Med. 2011 Feb 1;52(2):186-7. Epub 2010 Nov 30. 
Outcome 
I've heard that skin 
cancer is slow to 
develop. I'm 78 years old. 
At my age, do I really 
need to wear sunscreen 
and otherwise protect 
myself from the sun? 
United States;Mayo Clinic health letter (English ed.);Mayo Clin Health 
Lett. 2011 Mar;29(3):8. 
Study 
design/ 
publication 
type 
Sunscreens: expectation 
and realization 
Diffey, Brian;Review;Denmark;Photodermatology, photoimmunology & 
photomedicine;Photodermatol Photoimmunol Photomed. 2009 
Oct;25(5):233-6. 
Study 
design/ 
publication 
type 
46 
 
 
Sunscreens as a 
preventative measure in 
melanoma: an evidence-
based approach or the 
precautionary principle? 
Diffey, B L;England;The British journal of dermatology;Br J Dermatol. 
2009 Nov;161 Suppl 3:25-7. 
Study 
design/ 
publication 
type 
Sunscreen revisited 
United States;The Medical letter on drugs and therapeutics;Med Lett 
Drugs Ther. 2011 Mar 7;53(1359):17-8. 
Study 
design/ 
publication 
type 
Ultraviolet radiation 
Gallagher, Richard P;Lee, Tim K;Bajdik, Chris D;Borugian, 
Marilyn;Review;Canada;Chronic diseases in Canada;Chronic Dis Can. 
2010;29 Suppl 1:51-68. 
Study 
design/ 
publication 
type 
Sunscreen and 
melanoma: what is the 
evidence? 
Gimotty, Phyllis A;Glanz, Karen;Comment;Editorial;United 
States;Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology;J Clin Oncol. 2011 Jan 20;29(3):249-50. 
Epub 2010 Dec 6. 
Study 
design/ 
publication 
type 
Prevalence study of nevi 
in children from 
Barcelona. Dermoscopy, 
constitutional and 
environmental factors 
Aguilera, Paula;Puig, Susana;Guilabert, Antonio;Julia, Marc;Romero, 
David;Vicente, Asuncion;Gonzalez-Ensenat, Maria A;Malvehy, 
Josep;Research Support, Non-U.S. Gov't;Switzerland;Dermatology 
(Basel, Switzerland);Dermatology. 2009;218(3):203-14. Epub 2008 Dec 
8. 
Outcome 
Skin cancer 
Goldberg, Leonard H;Editorial;United States;Journal of drugs in 
dermatology : JDD;J Drugs Dermatol. 2008 Nov;7(11):1031. 
Study 
design/ 
publication 
type 
Increased melanoma 
after regular sunscreen 
use? 
Goldenhersh, Michael A;Koslowsky, Meni;Comment;Comparative 
Study;Letter;United States;Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology;J Clin Oncol. 2011 Jun 
20;29(18):e557-8; author reply e859. Epub 2011 May 2. 
Study 
design/ 
publication 
type 
Parental sun-protective 
regimens and prevalence 
of common melanocytic 
naevi among 7-year-old 
children in Sweden: 
changes over a 5-year 
period 
Karlsson, M A;Wahlgren, C F;Wiklund, K;Rodvall, Y;Research Support, 
Non-U.S. Gov't;England;The British journal of dermatology;Br J 
Dermatol. 2011 Apr;164(4):830-7. doi: 10.1111/j.1365-
2133.2011.10214.x. 
Outcome 
Factors related to being 
sunburnt in 7-year-old 
children in Sweden 
Rodvall, Ylva E;Wahlgren, Carl-Fredrik;Ullen, Henrik T;Wiklund, Kerstin 
E;England;European journal of cancer (Oxford, England : 1990);Eur J 
Cancer. 2010 Feb;46(3):566-72. Epub 2009 Oct 6. 
Outcome 
Ultraviolet radiation: a 
hazard to children and 
adolescents 
Council on Environmental Health;Balk, Sophie J;Review;United 
States;Pediatrics;Pediatrics. 2011 Mar;127(3):588-97. Epub 2011 Feb 
28. 
Study 
design/ 
publication 
type 
Sunscreens for non-
dermatologists: what you 
should know when 
counseling patients 
Stechschulte, Sarah A;Kirsner, Robert S;Federman, Daniel 
G;Review;United States;Postgraduate medicine;Postgrad Med. 2011 
Jul;123(4):160-7. 
Study 
design/ 
publication 
type 
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The good, the bad, and 
the ugly of sunscreens 
Berwick, M;United States;Clinical pharmacology and therapeutics;Clin 
Pharmacol Ther. 2011 Jan;89(1):31-3. 
Study 
design/ 
publication 
type 
Sunscreen products: 
what do they protect us 
from? 
Couteau, C;Couteau, O;Alami-El Boury, S;Coiffard, L J 
M;Netherlands;International journal of pharmaceutics;Int J Pharm. 2011 
Aug 30;415(1-2):181-4. Epub 2011 Jun 12. 
Population 
Role of UV light in 
photodamage, skin 
aging, and skin cancer: 
importance of 
photoprotection 
Gonzaga, Evelyn R;Review;New Zealand;American journal of clinical 
dermatology;Am J Clin Dermatol. 2009;10 Suppl 1:19-24. doi: 
10.2165/0128071-200910001-00004. 
Study 
design/ 
publication 
type 
The latest on skin 
photoprotection 
Gonzalez, Salvador;Fernandez-Lorente, Manuel;Gilaberte-Calzada, 
Yolanda;Review;United States;Clinics in dermatology;Clin Dermatol. 
2008 Nov-Dec;26(6):614-26. 
Study 
design/ 
publication 
type 
Skin cancer: more than 
skin deep 
Gordon, Randy M;United States;The Nurse practitioner;Nurse Pract. 
2009 Apr;34(4):20-7; quiz 27-8. 
Study 
design/ 
publication 
type 
Moderation is best also in 
sunbathing 
Hannuksela, Matti;English Abstract;Review;Finland;Duodecim; 
laaketieteellinen aikakauskirja;Duodecim. 2011;127(13):1381-4. 
Non- 
English 
The Second National 
Sun Survey: Overview 
and Methods 
Marrett LD, Northrup DA, Pichora EC, Spinks MT, Rosen CF.  
The Second National Sun Survey: overview and methods. Can J Public 
Health. 2010 Jul-Aug;101(4):I10-3. 
 
Outcome 
Predictors of sun protecti
on behaviors 
and severe sunburn in 
an international 
online study. 
 Bränström R, Kasparian NA, Chang YM, Affleck P, Tibben A, Aspinwall 
LG, et al. Predictors of sun protection behaviors and severe sunburn in 
an internationalonline study. Cancer Epidemiol Biomarkers Prev. 2010 
Sep;19(9):2199-210.  
 
Population 
Outdoor work and skin 
cancer incidence: 
a registry-
based study in Bavaria. 
Radespiel-Tröger M, Meyer M, Pfahlberg A, Lausen B, Uter W, Gefeller 
O.  Outdoor work and skin cancer incidence: a registry-
based study in Bavaria. Int Arch Occup Environ Health. 2009 
Feb;82(3):357-63.  
 
Intervention 
Relationship between su
n exposure and melanom
a risk for tumours in differ
entbody sites in a large 
case-control study in a 
temperate climate. 
Newton-Bishop JA, Chang YM, Elliott F, Chan M, Leake S, Karpavicius 
B, et al. 
Relationship between sun exposure and melanoma risk for tumours in 
different body sites in a large case-control study in a temperate climate. 
Eur J Cancer. 2011 Mar;47(5):732-41. 
 
Intervention 
Sun exposure and melan
oma risk at different latitu
des:a pooled analysis of 
5700cases and 7216 
controls. 
 Chang YM, Barrett JH, Bishop DT, Armstrong BK, Bataille V, Bergman 
W, et al. Sun exposure and melanoma risk at different latitudes: 
a pooled analysis of 5700 cases and 7216 controls. Int J 
Epidemiol. 2009 Jun;38(3):814-30.  
 
Intervention 
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Appendix G: Sample Data Extraction Table RCT and Case Control Studies 
Study Characteristics:  
Study ID First 
Author’s 
Last Name 
Year  Trial 
Name 
Country  Overall 
Sample 
Size  
Group 
Sample 
Size 
Aim of 
Study  
Study Design Level of 
Randomizatio
n 
Informed 
Consent 
Obtained
?  
92 PM  
 
Green, 
Adele 
 
2011 Reduced 
Melanom
a After 
Regular 
Sunscree
n Use 
 
Australia,  
Queenslan
d township 
of 
Nambour 
 
1621 Tx: 791 
(666 active 
and 125 
passive) 
Cx: 797 
(673 
active, 124 
passive  
Effect of 
daily 
sunscreen 
use (and 
beta-
carotene) on 
BCC, SCC, 
and 
melanoma 
(incidence) 
Randomized, 
Controlled, Trial 
Individually. 
Using a 
computer 
generated 
randomization 
list 
 
Yes 
Ethical 
Approval 
Obtained?  
Recruitme
nt Strategy  
Study 
Setting 
Study 
Duration 
in 
Months 
Funding 
Source  
Inclusion 
Criteria 
Exclusion 
Criteria  
Any 
subgroups 
analyzed? 
 
Baseline age 
mean (SD) 
(overall and by 
group) 
 
Baseline % 
female (overall 
and by group) 
 
Skin 
reaction 
to acute 
sun: 
 
Yes  Randomly 
sampled 
from the 
Nambour 
electoral roll 
(enrollment 
is required 
by law) 
 
Clinic 
 
Active: 4 
years. 
Follow 
up: 11 
years  
 
Adele C. 
Green.  
L Oreal 
Recherche  
 
Randomly 
selected. 
Must 
return 
initial 
survey. 
 
None.  Did 
not exclude 
patients 
with 
previous 
melanoma 
 
Beta 
carotene 
use.  
 
Tx and Cx: 
55%<50, 20% 
50-59 25%>60 
 
Tx: 56%     
 Cx: 56% 
 
Tx: Burn 
never tan: 
21 Burn, 
then tan 
68 only tan 
11   Cx: 
Burn never 
tan: 21 
Burn, then 
tan 68 
Only tan 
11 
50 
 
 
Baseline 
Skin 
Phenotype 
 
Total Sun 
Exposure 
 
Vacations 
 
Number of 
Outdoor 
Jobs 
 
Total 
Recreational 
Sun 
Exposure 
 
Protective 
Gear Use?  
 
Baseline 
Sunburn: 
Number or 
previous 
 
Other 
Baseline 
Confounders 
Considered 
 
Other Baseline 
Population 
Characteristics 
 (if clinically / 
significantly 
different 
between 
groups) 
 
Comments 
 
Tx:  
Fair 56% 
Medium 37% 
Olive/brown 
7%   
Cx:  
Fair 55% 
Medium 39% 
Olive/brown 
6% 
 
Clinical 
elastosis of 
the neck:  
Cx:  
None 23%  
 + 45%   
++ 31% 
Tx: 
None 21% 
 + 49%  
++ 30% 
Not 
Reported 
 
Tx:  
mainly 
outdoors 
20% 
Indoors and 
outdoors 
35% 
mainly 
indoors 45 
 Cx:  
mainly 
outdoors 17 
indoors and 
outdoors 39 
mainly 
indoors 44 
Not Reported 
 
Not Reported Tx:  
none 12% 
once 16% 
2-5 45 % 
>5 27%   
Cx:  
none 11% 
once 18% 
 2-5 44%  
>5 27% 
 
Nevi on 
back:  
Tx:  
none 17% 
1-10 68%  
>11 15% 
CX:  
none 16% 
1-10 67%  
>11 17 % 
Previous 
history of 
skin cancer: 
Tx: yes 25% 
Cx: yes 26%  
No Differences 
 
Did not 
exclude 
people with 
a previous 
history of 
melanoma 
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Intervention:  
Group 1 
(active 
intervention)  
Duration of 
Intervention 
Format of 
Intervention 
Intensity of 
Intervention 
Delivery of 
Intervention 
Measurement 
of 
Compliance 
with 
Intervention 
Measurement 
of Sun 
Exposure 
Measurement 
of Other 
Photo-
protection 
 
Control 
group 
intervention  
 
Integrity 
(was the 
outcome 
delivered as 
intended) 
 
Daily 
sunscreen 
use. Patients 
not blinded. 
Free 
unlimited 
supply of 
sunscreen 
with 
instructions 
to apply it 
daily during 
active phase. 
4 years 
 
Applied to 
head, neck, 
and arms 
hands every 
morning. 
With 
reapplication 
advised after 
sweating, 
bathing, or 
long sun 
exposure. 
 
SPF 16 
 
By the 
patient 
 
Measured 
weights of 
returned 
sunscreen 
bottles. 
Questionnaires 
asking 
average 
frequency of 
use in a 
normal week. 
 
After active 
trial 
participants 
followed up 
with biannual 
or annual 
questionnaires 
asking about 
average time 
outdoors and 
average 
sunscreen 
use. Sun 
exposure 
during the 
trial: Tx: 79% 
Cx: 77% 
spent less 
than 50% of 
weekend time 
outside.   
Sun protection 
methods 
similar during 
and after the 
trial: 
approximately 
60% sought 
shade, 75%  
usually wore 
hats (in both 
groups) 
Discretionary 
sunscreen 
use of any 
SPF. 
 
Sunscreen 
use:  Tx: 
approximately 
75% 
compliance.  
Cx: 38% no 
sunscreen 
use. 35% 
once or twice 
a week at 
most.  
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Outcomes:  
Change 
in 
Melanom
a 
Incidence 
Measurement of 
Outcome 
Results: Other 
Outcomes 
Measured  
Selective 
Reporting? 
Incomplete 
Outcome 
Data 
Sub-
analysis 
Morbidity Morality Other: 
quality of 
life, sick 
days, costs, 
legal issues, 
employment 
stability (by 
group) 
 
Harms (ex. 
Skin irritation, 
allergic 
reaction, 
psychological 
harm) 
 
Invasive 
melanoma 
HR 0.27 
(95% CI 
0.08 to 
0.97.)  
All 
melanoma 
HR 0.50 
(95% CI 
0.24 to 
1.02) 
 
Review of each 
diagnosed 
melanoma by two 
expert 
dermatopathologists 
-blinded to groups.  
Dermatologists 
performing physical 
exams also blinded. 
Also checked cancer 
registry.   Did not 
include melanoma 
diagnosed in the first 
year.  
 
36 primary 
melanomas 
(n=22 in 
situ, n=14 
invasive).  3 
people had 
melanoma 
diagnosed in 
1st year 
excluded.  
Total 11 in 
sunscreen 
and 22 in 
control.  
Average 
thickness 
0.53mm 
sunscreen 
and 1.2mm 
in controls 
(p=.08) 
 
After the 
trial- 3.8 and 
3.9 hrs 
spend 
outdoors 
during the 
week. 
Sunscreen 
use after the 
trial Tx: 25% 
cx: 18% 
 
Reported 
significant 
and non-
significant 
findings.  
 
Have 
outcome 
data 
(melanoma) 
on all 
participants 
active and 
passive. 
 
Multivariable 
proportional 
hazards 
regression 
with sex, 
skin type, 
nevi #, prev 
skin cancer 
hx, sun 
exposure 
Minimal 
effect on 
HR- 0.49 
Beta 
carotene use 
also 
randomized 
and 
measured.  
 
By the end 
of 2006, 
11% 
including 1 
who died 
from 
melanoma 
diagnosed 
in 1978. 
87 in 
sunscreen 
and 86 in 
controls 
 
Not 
reported 
 
Not reported 
 
Not reported 
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Quality Assessment:  
Was 
randomization 
adequate? 
 
Was 
allocation 
concealment 
adequate? 
 
Were groups 
similar at 
baseline? 
 
Were outcome 
assessors 
masked? 
 
Were care 
providers 
masked? 
 
Were 
patients 
masked? 
 
Was overall 
attrition 
≥20%?  
 
Was 
differential 
attrition 
≥15%? 
 
Did the 
study use 
ITT 
analyses?  
 
Drop outs/ 
cross overs?  
 
Yes 
 
Simple 
computer 
randomization.  
Use of a 
computer is 
adequate.  
 
Yes 
 
Yes. The 
dermatopathologists 
were masked.  
Don’t think 
statisticians were 
masked.  
 
Yes- 
Dermatologists 
conducting  
baseline skin 
examinations 
 
No  
 
No 
 
No 
 
Yes 
 
1 in each 
group withdrew 
consent.  125 
and 124 in 
each group 
became 
passive 
participants. 
Another 190 
and 180 
became 
passive during 
follow up. 
Potential for 
selection bias 
(+ to +++) 
explain 
 
Measurement 
of exposure/ 
intervention= 
equal, valid, 
reliable.  
 
Potential for 
measurement 
bias (+ to 
+++) explain 
 
Potential for 
confounding (+ to 
+++) explain 
 
Results: 
magnitude 
and direction  
 
Harms 
evaluated? 
 
Clinical/publ
ic health 
importance? 
 
Internal 
Validity  
(poor, fair, 
good) 
External 
Validity 
(poor, fair, 
good)  
Overall 
Quality 
Judgment 
(poor, fair, 
good) 
* Computer 
randomization. 
Groups 
comparable at 
baseline. Table 
1 shows similar 
groups. No 
Same care 
besides 
intervention 
and same 
length of follow 
up. Patients 
not blind. 
Dermatologist 
* 1/2  
 
*Sex, Age, Skin 
color, skin reaction 
to the sun, previous 
occupations, # 
sunburns, Nevi, 
Previous Skin 
cancer history, 
clinical elastosis of 
Daily 
sunscreen 
does reduce 
the risk of 
melanoma. 
Not significant. 
 
No 
 
High Good 
 
Fair- only 
one state in 
Australia. 
Different 
genetic 
type of 
melanoma? 
Fair  
54 
 
 
differential loss. 
 
and 
pathologists 
were blinded. 
Groups equal 
in study 
completion.  
Did not say 
what 
happened to 
those who did 
not complete 
the study. 
Good definition 
of outcome. 
There are 
some 
problems with 
melanoma 
diagnoses and 
consensus 
among 
dermatologists.  
 
the neck.  Groups 
equal due to 
randomization.  
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Sample Data Extraction Table for Systematic Reviews: Study Characteristics, Outcomes, and Quality Rating.   
Study ID First 
Author’s Last 
Name 
Year  Trial Name Country  Study 
designs 
included 
 
Aims of review- 
Key questions 
 
Time 
Period 
Covered 
 
Characteristics 
of included 
studies 
 
Characteristics 
of included 
populations 
134 PM 
 
Kutting, 
Birgitta 
 
2010 
 
UV-induced skin 
cancer at the 
workplace and 
evidence-based 
prevention 
 
Germany, 
Erlangen 
 
Case-
control, 
systematic 
review, risk 
estimation 
model 
 
"How effective 
are the 
recommended 
strategies for 
prevention of 
occupationally 
induced skin 
cancer and which 
recommendations 
on prevention of 
occupational 
exposure are 
useful? How can 
employees at risk 
be characterized?  
 
Not 
reported.   
Final 
articles 
from 1997 
to 2009 
 
Mostly case 
control (10) 1 
SR, 1 risk 
estimation.  
Mostly 
addressed SCC 
and BCC.  Only 
two looked at 
melanoma. One 
looked at ocular 
melanoma. 
 
Outdoor 
workers, 
farmers, >6hrs 
work outside, 
mountain 
guides, PE 
teachers, 
postmen, 
welders, 
fluorescent 
lighting at work. 
 
Change in 
Melanoma 
Incidence 
Measurement 
of Outcome 
Results: Other Outcomes 
Measured  
Selective 
Reporting? 
Incomplete 
Outcome 
Data 
Sub-analysis Morbidity Morality Other: quality 
of life, sick 
days, costs, 
legal issues, 
employment 
stability (by 
group) 
 
Not assessed 
 
NA Radespiel: CMM 
not associated 
with outdoor work.  
Lichte: CMM (0.01 
Final outcome for 
sunscreen: cover 
studies not 
evaluated in SR 
NA NA NA Not 
Assessed 
Not Assessed Not Assessed  
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vs. 0%)  Risk 
factor for CMM- 
severe sunburns.  
 
in sunscreen 
recommendation.    
Says melanoma 
increased or no 
effect with 
sunscreen use.  
Reports on two 
previous meta-
analyses not 
included in the 
study.  And 
epidemiological 
studies that show 
it might have an 
effect 
Harms (ex. 
Skin Irritation, 
Allergic 
Reaction, 
Psychological 
Harm) 
 
Review 
based on a 
key focused 
question?  
 
Comprehensive 
Literature 
search? 
 
Standard 
method to 
appraise 
Internal Validity 
Appraisal 
of included 
studies 
 
Publication 
bias 
addressed? 
 
Statistically 
analysis 
adequate? 
 
Relevance 
and 
recency 
of key 
question 
to our 
question? 
Validity of final 
conclusions? 
 
Overall Quality 
Rating (poor, 
fair, good)  
Allergic and 
photo-allergic 
reactions to 
active 
ingredients in 
sunscreen are 
uncommon.  
Vitamin D not 
effected by 
sunscreen 
use.  
 
** Yes.  
Actually two 
unrelated 
questions.  
Don’t think the 
studies they 
found can 
actually 
answer their 
key questions. 
 
* Searched 
Pubmed and 
Cochrane library 
in mars.  Do not 
include flow 
diagram or 
inclusion/exclusion 
criteria.  Do 
include list of 
search terms.  Not 
sure how they 
decided on final 
articles or number 
of reviews.  Do not 
* Not reported. 
Methods fail to 
give us 
information about 
their process.  
They include 
many studies not 
included in the 
SR in the 
discussion/results 
section.  Methods 
section talks 
about the 
strength of a SR. 
* Did not 
quality 
appraise 
studies.  
 
No 
 
NA 
 
Poor- did 
not answer 
our 
question 
specifically 
with 
included 
studies.   
 
Poor- not based 
on studies 
included in the 
SR.  
 
Poor 
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include details 
about the process.   
 
But they don’t 
include 
information that 
helps us to figure 
out if they 
actually did a SR.  
No information on 
how they 
conducted the 
quality rating or if 
it was done at all.  
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